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Abstract 
The South African government is currently discussing various alternative approaches to the 
further expansion of antiretroviral treatment (ART) in public-sector facilities.  
We used the EMOD-HIV model, a HIV transmission model which projects South African HIV 
incidence and prevalence and ARV treatment by age-group for alternative combinations of 
treatment eligibility criteria and testing, to generate 12 epidemiological scenarios. Using data 
from our own bottom-up cost analyses in South Africa, we separate outpatient cost into non-
scale-dependent costs (drugs and laboratory tests) and scale-dependent cost (staff, space, 
equipment and overheads) and model the cost of production according to the expected future 
number and size of clinics. On the demand side, we include the cost of creating and sustaining 
the projected incremental demand for testing and treatment.  
Previous research with EMOD-HIV has shown that more vigorous recruitment of patients with 
CD4 counts less than 350 is an advantageous policy over a five-year horizon. Over 20 years, 
however, the model assumption that a person on treatment is 92% less infectious improves the 
cost-effectiveness of higher eligibility thresholds, averting HIV infections for between $1,700 and 
$2,800, while more vigorous expansion under the current guidelines would cost more than 
$7,500 per incremental HIV infection averted.  
Based on analysis of the sensitivity of the results to 1,728 alternative parameter combinations at 
each of four discount rates, we conclude that better knowledge of the behavioral elasticities 
could reduce the uncertainty of cost estimates by a factor of 4 to 10. 
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Executive summary 
Background  
The South African government is considering alternative policies for scaling up publicly funded 
antiretroviral treatment (ART) for HIV/AIDS. Policies under discussion differ from previous policy 
in two dimensions: eligibility criterion and recruitment strategy. A number of analyses have 
considered the cost, cost effectiveness and/ or cost benefit of alternative eligibility criteria and 
recruitment strategies for a number of low- and middle income countries, including South Africa, 
but the detail with which cost was treated in these studies does not mirror the detail of the 
epidemiological projections, with authors often assuming the cost per patient-year of treatment 
would remain constant over time despite increases in the size of the treatment cohort by several 
hundred percent. In particular, economies of scale and the cost of generating the additional 
demand necessary for the assumed increase in recruited patients have not yet been not taken 
into account. 
In South Africa HIV infected persons have been eligible for publicly funded ART if their CD4 
count is less than a threshold of 350 cells per microliter or they test positive for tuberculosis or 
are children. Recruitment has been active, but has succeeded in linking to ART fewer than 70 
percent of those eligible under these guidelines [34]. The baseline scenario, which we refer to 
as the “current guidelines eligibility, status quo recruitment” (CG.SQ) scenario, projects to 2033 
the epidemiological and cost consequences of a continuation of recent policies. We treat the 
projected cost through 2033 of this CG.SQ scenario as a sunk cost, to which the government is 
unalterably committed. We investigate the impact of factors such as scale, level, and location of 
care on the additional cost of expanding ART treatment beyond current guidelines following 
eleven possible alternative policy scenarios.  
Methods  
Over a twenty-year projection horizon, 2014-2033, we compared the projected epidemiological 
consequences and facility-level costs of eleven policy scenarios to the “current guidelines, 
status quo” (CG.SQ) scenario described above. The eleven scenarios are combinations of four 
alternative eligibility criteria and two alternative recruitment strategies. Alternative eligibility 
strategies and their abbreviations are: A CD4 threshold of 500 or less (abbreviated as “500”), all 
HIV positive people (also called “universal test and treat” or “UTT”), HIV positive individuals with 
seronegative partners (called “discordant couples” or “DC”) and HIV positive women who are 
pregnant (called “pregnant women” or “PW”). For the CG, the 500 and the UTT criteria, we 
explored both a “status quo” and a more ambitious “uniform expansion” (UE) recruitment 
strategy, which assumes increased testing and immediate ART initiation amongst 80% of the 
(eligible) population. For the DC and PW eligibility strategies, we additionally modeled an 
intermediate recruitment strategy called “prioritized expansion” (PE), which covers 80% of the 
targeted sub-population, while the rest of the population would continue to access testing and 
care at the “status quo”.  
Epidemiological data 
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Projections to 2033 of the number of HIV tests, HIV infections, and patients in HIV care were 
obtained from the EMOD-HIV model, a stochastic microsimulation model that includes 
incorporates reduced transmission from those on ART. The model has been calibrated to fit 
multiple sources of epidemiological data on the South African HIV epidemic (including 
prevalence by age, gender, and year; ART initiations by gender and year; CD4 counts at ART 
initiation; and testing by age and gender) The model provided outputs on the number of adults 
and children tested, in pre-ART care, on ART, in treatment failure and lost from care by CD4 cell 
count stratum (defined as >500, 350-500, 200-349, 100-199, and <100 cells/microliter, or 
corresponding pediatric CD4% and cell count values), and the number of new HIV infections for 
each year between 2014 and 2033.  
Cost data 
Data on the cost of testing and on the average outpatient and inpatient cost for an infected 
individual receiving no HIV care, pre-ART care, or ART came from our own bottom-up cost 
analyses of HIV-related care in South Africa. We separated outpatient cost into scale-
independent costs (cost of drugs and laboratory tests, for which prices are mandated centrally 
for the entire public sector), and scale-dependent cost (staff, space, equipment and overheads) 
which we varied with the expected size of each clinic. For this we calculated the distribution of 
patients into clinics and into urban/ rural districts based on the distribution and size of ART 
clinics in June 2013 and assumptions about the likely growth in the size of each facility and in 
the number of clinics overall. Lastly, under each scenario except the baseline scenario of the 
current guidelines at current levels of testing, treatment uptake and retention, we also included 
the cost of demand creation for testing and of enabling improved retention for every additional 
patient who tested and initiated ART incremental to those patients in the baseline scenario in 
the analysis. For testing, we added the cost of a mobilization event per tested patient. In order 
to enable patients to present themselves for quarterly appointments at the ART clinic, we added 
an outreach cost per incremental patient which, at our assumed elasticities of demand, would 
be sufficient to attract the number of patients to that facility that are predicted by the given 
epidemiologic scenario. We calibrated these elasticities so that for a modest expansion the 
annual per-patient outreach cost would approximately equal the typical cost of four trips to a 
health center at ZAR 50 (USD 5) for an urban clinic and ZAR 30 (USD 3) for a rural clinic per 
single round trip. Outreach cost per patient can rise to a multiple of these benchmark values in 
high coverage scenarios or in high coverage clinics. 
We then calculated cost-effectiveness (cost per infection averted) and cost utility (cost per 
disability-adjusted life year (DALY) averted). For the latter, we summed the total number of life 
years lived by HIV+ people in any type of care or health state, weighted by health-state specific 
disability weights, between mid-2014 and mid-2033 under each scenario and calculated the 
incremental number of DALYs of each scenario over the baseline scenario. 
Results 
Number of patients on ART 
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Under the current guidelines and trends in testing, linkage to care and losses to retention 
(CG.SQ), 2.4 million adults and 202,067 children are estimated to be on treatment by mid-2016, 
and 3.4 million adults and 135,424 children by 2033. If the current guidelines were kept, but 
testing, linkage to care and retention were improved to 80% each (CG.UE), these numbers 
would increase to 3.7 million adults and 236,471 children in 2016, and 5.3 million adults and 
103,789 children in 2033. Under all other uniform expansion (UE) scenarios, there are more 
patients expected to be on treatment by mid-2016, and less by mid-2033, than under CG.UE; 
there is in fact an inverse relationship between the number of patients on treatment by mid-2016 
and those on treatment by mid-2033 for all scenarios. This pattern of higher enrollment in early 
years followed by fewer patients in later years is a consequence of the epidemiological model’s 
assumption that people on treatment are less likely to transmit HIV infection.  
Development of undiscounted HIV-related cost over time 
In our analysis, despite the incorporation of the prevention benefits of treatment, none of the 
scenarios achieves an annual cost less than the baseline of current guidelines with status quo 
recruitment before 2033, The cost trajectories in most scenarios flatten towards the end of the 
projection period, and the cost trajectories of most of the SQ scenarios (whose incremental cost 
over the baseline scenario per year is very small throughout) dip below the cost of the baseline 
scenario (CG.SQ) in the last years of the projection period, suggesting that the annual cost of 
any of these scenarios would eventually be lower than in the baseline and thus would eventually 
produce annual cost saving. The same is true for the cost of the PW.PE scenario. 
Total HIV-related cost 
At the discount rate of 3% and under our other central assumptions, the total cost over 20 years 
for the current guidelines at status quo (CG.SQ) is expected to be close to USD 36 billion, 
equivalent to an annual payment of US$2.4 billion. For reference, the discounted cost for the 
current mid-term expenditure framework of 2014-2016 is USD 3.6 billion, or about US$1.2 billion 
per year. The large contribution to cost of non-ART inpatient and outpatient services under the 
SQ scenarios is greatly reduced under the UE scenarios, but its place is filled by the large 
additional expenditure for testing. The two parts of ART costs we have assumed to be unrelated 
to the scale of a facility’s work load, the cost of ARVs and labs, rise proportionately with the 
number of patients on treatment, as does inpatient cost for patients on ART. The component 
that rises disproportionately with the number of patients is the cost of outreach. Under our 
central assumption set, we set the elasticities of urban and rural demand to equal respectively 
0.1 and 0.5. We assume cost of outreach to be zero in the baseline CG.SQ scenario and to 
barely appear at all under the other SQ or the PE scenarios. This is because none of these 
scenarios is projected to require a large percentage increase in patients. However, all five of the 
UE scenarios as well as the DC.PE scenario are expected to greatly increase their recruitment 
of patients.  
Cost effectiveness 
Improving testing, linkage to care and retention under the current eligibility in the CG.UE 
scenario would result in a total cost over 20 years of USD 14.6 billion and in a reduction of new 
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infections by 44% to 1.9 million. This results in a cost per infection averted of USD 7,559, the 
highest cost per infection averted of all scenarios, including all other uniform expansion sub-
scenarios. 
The most cost-effective option in terms of cost per infection averted is to expand ART eligibility 
to pregnant women, either while maintaining the status quo for linkage and retention (Scenario 
PW.SQ costs $1,692 per infection averted) or while improving their linkage and retention and 
maintaining the status quo for everyone else (Scenario PW.PE costs $1,979 per infection 
averted). On the other hand, expanding eligibility for discordant couples, either as prioritised or 
as uniform expansion (DC.PE or DC.SQ), costs more than US$6,600 per HIV infection averted 
and is the least cost-effective option of all PE or SQ scenarios.  
When maintaining the current status quo for testing, linkage to care and retention, expanding 
eligibility to discordant couples or pregnant women would have little effect on either cost or 
infections averted (although for the DC.SQ scenario, the increments in both cost and the 
number of infections averted is too small for the cost per infection averted result to be 
meaningful). This is because coverage of ART is already high in pregnant women compared to 
the general population, and current levels of partner testing are relatively low, so that few 
additional people would be reached by expanded guidelines unless effort is made to also 
encourage testing and linkage to care. Expansion of eligibility guidelines to include persons with 
a CD4 cell count of <500 cells/microl or all infected individuals would significantly increase both 
cost and infections averted, costing about $2,700 per infection averted under the SQ strategy or 
$5,283 per infection averted under the UE strategy. Universal test and treat guidelines would 
cost about 7% less per infection averted than would a <500 strategy. 
Cost utility  
The results of the cost-utility analysis mirror those of the cost-effectiveness analysis. As before, 
the most expensive and least cost-effective option, both in terms of cost per infection averted 
and by cost per DALY averted, is the uniform expansion of the current guidelines- every other 
uniform expansion scenario, including universal test and treat, becomes less expensive than the 
current guidelines over time, due to cost savings associated with the reduction in HIV 
transmission under high levels of population ART coverage.  
Sensitivity analysis 
We studied the sensitivity of results by first holding constant the central assumptions and 
considering each of several “expansion paths” from the baseline scenario to expanded eligibility 
and enhanced recruitment, and then by allowing all assumptions to vary over plausible ranges. 
A remarkable feature of the expansion paths for several scenarios is their kinked shape. (An 
“expansion path” is defined as the sequence of cost and utility combinations which start from 
CG.SQ and proceed step-by-step to a) supplement current eligibility by including specific 
population X, where X = {500, UTT, DC, PW}, but with current patterns of testing and service 
uptake (scenario X.SQ); b) expanding testing and service provision to provide prioritized access 
for population X (scenario X.PE) (where available); and c) further expand testing and service 
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provision to provide uniform access to 80% of the population (scenario X.UE).) Under the 
current eligibility guidelines (CG) and those expanded to include people with CD4 under 500 
(500), all HIV positives (UTT) or pregnant women (PW). Initial expansion can be a good buy, but 
subsequent expansion to a UE scenario is always less cost-effective. We did a total of 13,824 
computations of the model, 6,912 for each of two assumptions about the patients who would 
require outreach cost. We always assumed that outreach costs would be paid to all patients in 
excess of those who would seek care under the CG.SQ scenarios. For half the scenarios, we 
defined this excess for the facility as a whole; for the other, we calculated the increment 
between the two scenarios in the number of patients in each CD4 category, and applied 
outreach costs to those patients in health states with positive increments only. For each of these 
two assumptions about which patients would require outreach expenditure, we computed 12 
scenarios x 4 discount rates x 3 scale elasticities x 4 distribution patterns x 12 elasticity of 
demand combinations. Across these combinations, half of the cost-effectiveness estimates lie 
between $3,000 and $8,000 per HIV infection averted, with extreme values as low as $4 and as 
high as $33,000 per infection averted. Most of the variation is driven by variation in the demand 
side parameters.  
Our sensitivity analysis also shows that the distinctive concave kink in the expansion paths is 
robust to all tested variations in assumptions and more pronounced at lower elasticities of 
demand or when the number of facilities is not expanded to accommodate new patients. 
Conclusions 
We combined the outputs of an epidemiological and a cost model of the HIV epidemic in South 
Africa to calculate the incremental cost effectiveness of a range of strategies to expand eligibility 
beyond current guidelines. Previous research with EMOD-HIV has shown that more vigorous 
recruitment of patients with CD4 counts less than 350 appears to be an advantageous policy 
over a five-year horizon. Over 20 years, however, the model assumption that a person on 
treatment is 92% less infectious improves the cost-effectiveness of higher eligibility thresholds 
over more vigorous recruitment at the lower threshold of 350, averting HIV infections for 
between $1,700 and $2,800 (under our central assumptions), while more vigorous expansion 
under the current guidelines would cost more than $7,500 per incremental HIV infection averted.  
Using the recent ART programme in South Africa as a baseline, we model the incremental cost 
per infection or DALY averted of each of 11 different policy alternatives for its expansion. In 
terms of total cost, all scenarios that maintain current trends in testing coverage, linkage to care, 
and retention in care (‘status quo’) have a very similar cost of around $36 billion over 20 years, 
while all scenarios that, for any given eligibility, assume uniform expansion of testing, linkage 
and retention for the entire population of eligible people (‘uniform expansion’), have a total cost 
over 20 years of $50 billion USD. Within these, expanding eligibility to discordant couples (at 
current testing and linkage levels) and all pregnant women (at current and improved testing and 
linkage levels) are the least costly options, followed by expanding eligibility to all patients with 
CD4 cell counts < 500 cells/microl and Universal Testing and Treatment, both at the current 
level of testing and linkage.  
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The incremental cost per infection averted is between $1,600 and $2,700 for all ‘status quo’ 
recruitment scenarios, regardless of the eligibility criteria. Among these, the prioritisation of 
pregnant women is the most cost-effective scenario, though it has little overall impact because 
HIV testing rates are already high amongst pregnant women due to high coverage of antenatal 
care in South Africa. All ‘uniform expansion’ scenarios have both greater cost and greater 
impact, and are more costly per infection averted. The same pattern emerges in terms of cost 
per DALY averted, although the difference between the scenarios are exaggerated as a result of 
the CD4 cell count-dependency of the disability weights for people not on ART.  
Expanding eligibility from the recent guideline requiring patients to have CD4 counts less than 
350 to either a threshold of 500 or to include all HIV-infected people (UTT) does not increase 
the present value of the stream of HIV/AIDS costs through 2033. Furthermore, the health 
benefits of expansion are greater under either the 500 threshold or the UTT rule, so that under 
both of these wider eligibility alternatives cost per infection averted and cost per DALY averted 
are significantly less than under current eligibility rules. The uniform expansion of the current 
guidelines has the highest cost per outcome of all scenarios 
Budgeting for universal coverage will require detailed country-specific estimates for the 
elasticities of supply and demand that we model here, and the calculation of not only numbers 
on treatment (as we have done here) but also prevalence and treatment need with far more 
granularity, possibly at the district or even clinic level. Furthermore, instead of subsuming all 
demand enhancing interventions into a single outreach cost, a more realistic model of demand 
would distinguish among elasticities with respect to travel vouchers, distance from home to 
facility, provider attitudes as well as characteristics of the patient, such as their CD4 cell count, 
income and education. As knowledge accumulates about the influence of such indicators, 
census and survey data on the exact geospatial locations of HIV infection can be used to build 
granular spatial models of demand which would offer the possibility of optimising the targeting of 
new facility construction and outreach services. These tools would help governments plan their 
own policies and help them in the increasingly competitive and demanding process of preparing 
investment cases to compete successfully for donor support.  
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Introduction 
The South African public-sector guidelines for adult ART are in the process of being revised. A 
central concern is the further expansion of ART eligibility for adults beyond the current 
thresholds (a CD4 cell count of <350 cells/microl or active TB disease). Among the options 
under debate are 
1. the extension of eligibility to all adults with CD4 cell counts <500 cells/microl; 
2. the provision of ART to the positive partner in serodiscordant couples regardless of 
CD4 cell count, together with a concomitant increase in couples testing; 
3. the extension of eligibility to all pregnant women regardless of CD4 cell count; 
4. the introduction of a universal test and treat policy with annual testing of the population 
and initiation on ART of every person identified as HIV-positive regardless of CD4 cell 
count.1 
A number of analyses have considered the cost, cost effectiveness and/ or cost benefit of some 
or all of these options for a number of low- and middle income countries, including South Africa 
[4-10]. A recent paper reviewed all modeled analyses of the cost or cost-effectiveness of ART, 
including those assuming an impact of ART on HIV transmission, and found that the detail with 
which cost was treated did not mirror the detail of the epidemiological projections, with authors 
often using uniform per patient cost despite increases in the size of the treatment cohort by 
several hundred percent [11].  
South Africa was also included as one of four countries in a recent coordinated analysis 
involving twelve different HIV transmission models to inform the 2013 WHO guidelines on earlier 
treatment initiation [12]. Here again, cost was differed by type of regimen and health state, but 
factors such as economies of scale and the cost of generating the additional demand necessary 
for the assumed transmission impact to take hold were not taken into account. 
In this analysis we treat the cost of continued care expansion through 2033 under current 
eligibility guidelines as a sunk cost, to which the government is unalterably committed. Under 
this assumption, we investigate the impact of factors such as scale, level, and location of care 
on the additional cost of expanding ART treatment beyond current guidelines following several 
possible alternative policy scenarios. For this, we apply synthesized evidence about variability of 
the cost of HIV testing and ART provision at different scales and levels of care, and model the 
additional cost of demand generation. Furthermore, we add the cost and impact of paediatric 
ART provision. In order to ensure comparability, we follow the methodology of the 12-model 
analysis as much as possible, especially in the calculation of the number of patients in care, 
survival, and cost-utility [12]. 
                                                          
1 These options are based on the 2013 WHO guidelines [1], the results of the HPTN052 study [2], WHO 
PMTCT Option B+ [3] and a scenario introduced by Granich at el 2009 [4], respectively. 
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Methods 
We compared each of the expansion options for adult ART eligibility to the current South African 
baseline of eligibility at a CD4 cell count of <350 cells/ microl or WHO status 3 (including TB). In 
order to answer questions regarding the cost effectiveness and cost utility of each of these 
options, we combined an existing model of the HIV epidemic in South Africa with output from an 
existing cost model used by the South African government for the calculation of the budget for 
the public-sector ART program over the last five financial years [13,14] as well as other recently 
published local cost data [15-17] and with disability weights from the recently updated Global 
Burden of Disease study [18].  
While this section aims to give an overview over methods, assumptions and data sources, more 
details on the epidemiological model can be found in Appendix A, and more details on the 
methods used in the economy evaluation, including mathematical derivations for each aspect, in 
Appendix B. 
Epidemiological data 
Data on the number of HIV tests and the number of patients in HIV care was obtained from the 
EMOD-HIV model, a stochastic microsimulation (patient-level) model developed by the Institute 
of Disease Modeling in Bellevue, WA, US. The model includes an impact of treatment on HIV 
transmission (see Appendix A for a detailed description of the model assumptions and 
functionality). The model has been calibrated to fit multiple sources of epidemiological data on 
the South African HIV epidemic (including prevalence by age, gender, and year; ART initiations 
by gender and year; CD4 counts at ART initiation; and testing by age and gender) and was 
included in the recent 12-model comparison exercise [12]. The EMOD-HIV model was altered 
for this analysis to include a representation of the HIV epidemic in children, including a cohort 
on treatment. Additionally, a tally of HIV-positive individuals lost from care at any stage (after 
HIV testing, during pre-ART care or after ART initiation) was added, with any patient not having 
linked to further care or returned for an ART visit within the last six months being counted as 
lost. The model provided outputs on the number of adults and children tested, in pre-ART care, 
on ART, in treatment failure and lost from care by CD4 cell count stratum (defined as >500, 
350-500, 200-349, 100-199, and <100 cells/microl, or corresponding paediatric CD4% and cell 
count values), and the number of new HIV infections for each year between 2014 and 2033.  
Cost data 
We combined this information with data on the cost of testing and on the average outpatient and 
inpatient cost for an infected individual receiving no HIV care, pre-ART care, or ART from a 
number of sources (see Table 1). The outpatient cost of ART provision was divided into two 
segments, depending on the likely variation of each cost item with the size of the outpatient 
clinic.  
Non-scale dependent cost 
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The cost of drugs and diagnostics was assumed not to vary by clinic size and was based on the 
average cost per adult or child in 2013/14 as projected by the National ART Cost Model [13,14]. 
This average cost was calculated by age group (1 adult and 3 child age groups) for four different 
types of care: treatment initiation, first-line treatment, first-line treatment failure, and second line. 
We included the cost of HIV counseling and testing of the entire tested population (not just HIV-
positives or people on ART) as a weighted average across two different modalities, facility-
based testing and mobile testing. 
  
13 
 
  
Table 1: Input cost parameters from South African National ART Cost Model 
Type of care Pre-ART First-line ART 
Second-
line ART 
Treatment 
initiation 
Treatment 
failure Source 
Annual cost of outpatient care (cost of drugs and laboratory tests only)+ 
Adults (>15 yrs) 53 79 416 79 10 
National ART Cost 
Model average for 
2013/14 [13,14] 
Children <1 yr 53 145 321 91 11 
Children 1-2 yrs 53 70 316 129 11 
Children 3-5 yrs 53 131 203 98 11 
Children 6-14 yrs 53 182 302 73 11 
CD4 cell count* [cells/microl] >500  350-500  201-349  100-200  <100  
Annual cost of inpatient care (urban)+ 
Adults (>15 yrs), not on ART - 57 - 80 128 188 [15] 
Adults (>15 yrs), on ART - 59 - 139 201 513 [15] 
Children <1 yr, not on ART -- 3,578 -- [16] 
Children <1 yr, on ART -- 1,660 -- [16] 
Children 1-2 yrs, not on ART - 45 - 71 123 123 
[15], adjusted for 
paediatric cost per 
patient-day equivalent 
based on [17] 
Children 1-2 yrs, on ART - 47 - 124 193 335 
Children 3-5 yrs, not on ART - 45 - 71 123 123 
Children 3-5 yrs, on ART - 47 - 124 193 335 
Children 6-14 yrs, not on ART - 45 - 71 123 123 
Children 6-14 yrs, on ART - 47 - 124 193 335 
Annual cost of inpatient care (rural)+ 
Adults (>15 yrs), not on ART - 27 - 105 160 228 [15] 
Adults (>15 yrs), on ART - 94 - 239 388 732 [15] 
Children <1 yr, not on ART -- 3,578 -- [16] 
Children <1 yr, on ART -- 1,660 -- [16] 
Children 1-2 yrs, not on ART - 21 - 93 154 149 
[15], adjusted for cost 
per patient-day 
equivalent based on 
[17] and urban/ rural 
difference in adult 
inpatient cost 
Children 1-2 yrs, on ART - 74 - 212 372 478 
Children 3-5 yrs, not on ART - 21 - 93 154 149 
Children 3-5 yrs, on ART - 74 - 212 372 478 
Children 6-14 yrs, not on ART - 21 - 93 154 149 
Children 6-14 yrs, on ART - 74 - 212 372 478 
Per-test cost of HIV counseling and testing+ 
per adult tested (facility-based) 11 [19] 
per adult tested (mobile testing) 15 Assumption 
per child tested (facility-based) 43 [19]** 
per child tested (mobile testing) 49 Assumption 
Cost of mobilisation event  23 [19] 
* or paediatric equivalent **plus cost of PCR test  +All costs expressed in 2013 US dollars. 
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Scale-dependent cost 
Unlike most projections of AIDS treatment costs, this study models the average cost of staff, 
space, equipment, and overheads as varying with the number of ART patients. Based on the 
actual size distribution of South African ART clinics in June 2013 [20] and alternative 
assumptions about the South African government’s choice between increasing the utilization of 
current facilities and adding new ones (see Table 2), we projected the future distribution of 
patients into clinics and into urban/ rural districts. We assumed cost to vary with clinic level 
(primary healthcare clinics, community clinics, district or regional hospitals, tertiary hospitals) as 
well as with scale. In the base case analysis, the cost adjustment factor was 1.05 for clinics, and 
0.79 for hospitals, based on data from a cost analysis of ART provision in 45 facilities in Zambia 
[21]. Based on a multi-clinic cost analysis of ART in a number of sub-Saharan African countries, 
including South Africa [22], we select a value of 0.8 as the central assumption for the scale 
elasticity and explore values of 0.6 and 1.0 in the sensitivity analysis. More details on the 
methods used in the estimation of scale-dependent cost is available in the section on 
“Expansion scenarios” further below. 
Table 2: Cohort distribution assumptions  
Parameter Value Source 
Additional percentage of patients on first-line ART moving to 
second line each year 0.8% 
National ART Cost Model average for 
2013/14 to 2016/17 [13,14] 
Percentage of people accessing facility-based testing (as opposed 
to mobile testing) 99.6% 
District Health Information System data 
for June 2013 [19] 
Distribution of pre-ART patients into levels of care   
 - primary healthcare clinics 54% 
 - community day/ health care centres 25% 
 - district/ regional hospitals 17% 
 - provincial tertiary hospitals/ national central hospitals 4% 
 
The future stream of costs is projected in constant 2013 USD. All cost data collected in ZAR are 
converted to USD at the current exchange rate of 1 USD = 9.89 ZAR. 
For cost-effectiveness and cost-benefit calculations, both costs and outcomes are subsequently 
discounted to the present value at 3%. We explore the impact of alternative discount rates in 
sensitivity analyses, including a value of 5%, the current repurchase rate of the South African 
Reserve Bank [23]. 
Cost-effectiveness analysis  
Using two alternative measures of effectiveness, we estimate the cost-effectiveness of each of 
the 11 scenarios in comparison to the current guidelines status quo (CG.SQ). For each 
calculated cost-effectiveness ratio, the numerator is defined as the present value of the future 
stream of costs under one of the 11 alternative policy scenarios minus the present value of the 
future stream of costs under the baseline scenario. The denominator of one set of cost-
effectiveness measures is defined as the present value of the future stream of HIV infections 
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under the baseline scenario minus the (presumably smaller) present value of the future stream 
of HIV infections under one of the 11 alternative policies. The cost-effectiveness ratios from this 
set of calculations yield the estimated cost per HIV infection averted. 
For consistency with [12], the denominator of a second set of cost-effectiveness measures is 
defined as the present value of the future stream of disability weighted [18] (see Table 3) life 
years lived by HIV+ people under one of the 11 alternative policy scenarios minus the 
(presumably smaller) present value of disability weighted life years lived by HIV+ people under 
the baseline scenario. The cost-effectiveness ratios from this set of calculations yield the 
estimated cost per additional healthy life year and can be interpreted as the cost per DALY 
averted.  
In all of these cost-effectiveness calculations, the same discount rate is used to compute the 
present values in the numerator and the denominator.  
  
Cost-benefit analysis  
Following a recent cost-benefit analysis of the investment of the Global Fund for AIDS, Malaria 
and Tuberculosis [24], we calculate the cost benefit ratio of each policy option by adding the 
averted cost of orphanhood and the value of additional productivity generated by each of the 11 
alternative scenarios in comparison to the baseline scenario of the current guidelines. The cost 
of orphan care was based on an update to [25] and is applied to the fraction of households 
estimated to live below the poverty line (upper bound) of R 577 (2009 ZAR) [26]. Productivity 
was valued as Gross National Income per working-age person and was weighted by CD4 cell 
count stratum and ART status using a summary of analyses of the impact of HIV and ART on 
employee productivity from [24]. The assumptions used in this analysis are summarized in 
Table 3. 
Table 3: Outcomes assumptions  
CD4 cell count* [cells/microl] >500  350-500  201-349  100-200  <100 Source 
Disability weights (adults and children) 
HIV-infected, not on ART 0.053 0.053 0.221 - 0.547 - [18] 
HIV-infected, on ART -- 0.053 -- [18] 
Productivity weights (adults of working age) 
HIV-infected, not on ART 1 1 - 0.2 - [24] 
HIV-infected, not on ART 1 1 - 0.75 - [24] 
Cost of orphan care in 2013 USD 
% of orphans needing care 
and support -- 56.8% -- Upper-bound poverty line [26] 
Cost per child aged      
 0-4 yrs -- 304 -- 
[25]  5-9 yrs -- 486 -- 
 10-18 -- 1,132 -- 
Value of productivity in 2013 USD 
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Gross National Income (GNI) 
per working-age person  -- 13,618 -- 
2012 GNI [27] divided by total 
population aged 20-65 from 
2011 national census [28] 
% of adult population assumed 
to be of working age 90% [24] 
   
Expansion scenarios 
We evaluated the total and incremental cost, cost effectiveness, cost-utility and cost-benefit of 
each of the four eligibility scenarios mentioned above, compared to the baseline scenario of the 
current South African treatment guidelines. Within each scenario, we varied assumptions about 
how expansion would take place, based on the analytical framework used in the 12-model 
analysis [12]: 
x “Status quo” (SQ): Estimated current patterns of testing and service uptake (linkage to 
care and retention in care, with values based on [29]) continue into the future. 
x “Prioritised expansion” (PE): Increased testing and immediate ART uptake amongst 
80% of the members of the specific subpopulation prioritised for immediate ART, while 
for the general population estimated current patterns of testing and service uptake 
continue into the future. (This sub-scenario only applies to the scenarios with discordant 
couples and pregnant women.) 
x “Uniform expansion” (UE): There are substantial increases in HIV testing and linkage 
such that 80% of infected persons undergo annual testing and, once tested HIV positive, 
semi-annual CD4 monitoring (if previously tested positive), and have the opportunity to 
initiate ART as soon as they are eligible. 
 
Together with the four eligibility options mentioned in the Introduction, this gives us a total of 12 
scenarios for analysis: 
1. Current guidelines (CG) 
a. Status quo (CG.SQ) 
b. Uniform expansion (CG.UE) 
2. Eligibility at 500 (500) 
a. Status quo (500.SQ) 
b. Uniform expansion (500.UE) 
3. Universal Test and Treat (UTT) 
a. Status quo (UTT.SQ) 
b. Uniform expansion (UTT.UE) 
4. Discordant couples (DC) 
a. Status quo (DC.SQ) 
b. Prioritised expansion (DC.PE) 
c. Uniform expansion (DC.UE) 
5. Pregnant women (PW) 
a. Status quo (PW.SQ) 
b. Prioritised expansion (PW.PE) 
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c. Uniform expansion (PW.UE) 
Demand- and supply-side cost considerations 
As mentioned above, previous efforts to model the cost of scaling up antiretroviral therapy in 
South Africa have assumed zero cost for demand generation and, with the exception of our own 
illustrative exercise [11], have modelled ART production as if all patients in the country were 
served by a single gargantuan hospital, with constant unit costs by patient type. In this paper we 
explore the influence on cost estimation of the relaxation of these implausible demand- and 
supply-side assumptions. 
Modeling the cost of production 
We used data on the size and distribution of ART clinics in South Africa based on the District 
Health Information System from June 2013 [20]. We then added functionality to the model that 
allows the analyst to set the maximum number of clinics that will be accredited for ART over the 
next 20 years, the distribution of new facilities into different clinic levels, and the shape of the 
clinic size distribution function. Based on an increasing body of literature [21,22,30,31], we 
selected a scale elasticity at 0.8 for the base case analysis. 
In our previous paper [11], we introduced to the literature on the modeling of antiretroviral 
treatment scale-up the distinction between two types of cost functions, which we termed the 
“accounting identity” cost function and the “flexible” cost function. Following the economics 
literature, we defined the accounting identity function as one which constructs an estimate of 
aggregate production cost by assuming that the average cost of output is fixed, so that total cost 
during a period is simply the product of the number of units of output during that period and the 
constant average cost. In contrast, we defined a “flexible” cost function as one that allows for 
production managers to achieve economies in response to changes in factor prices, scale of 
production and other relevant variables that affect their operating environment. Instead of 
starting with an average cost and multiplying by the units of output, the user of a flexible cost 
function starts by specifying that total cost at an individual facility is related to output and other 
facility characteristics by a parsimonious non-linear functional relationship and then divides total 
cost by output in order to derive average cost. Following this second more flexible approach, 
average cost is not necessarily constant over time and in practice tends to decline with the 
volume of output, displaying the pattern known as economies of scale.2 
As econometric studies of the cost of ART in representative and/or moderately sized samples of 
facilities have begun to appear in the literature, evidence has accumulated against the simplest 
accounting identity cost functions [21,22,30]. Estimates of economies of scale are typically 
statistically significant, with scale elasticities, where they are reported, ranging from 0.7 to 0.9.3 
                                                          
2 Economies of scale occur when a portion of costs are fixed, and a portion variable. More generally they occur 
because all factors of production, not just fixed factors, are used more efficiently when they can be spread over more 
units of output. A flexible cost function also characterises other aspects of the production technology which are 
obscured in an accounting identity, such as the degree to which various inputs to the production process can be 
substituted for one another and whether technological change primarily benefits labor or capital. In this paper, we 
ignore these other aspects of a cost function. 
3 An elasticity is the percentage impact on a dependent variable of a 1% increase in an independent variable. 
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When the elasticity of scale differs significantly from unity (ie, 1), ignoring the current and future 
size distribution of the ART treatment facilities can substantially bias estimates of future 
production costs, as we showed in our previous analysis [11].  
For this analysis, we benefit from a more complete census of South African ART facilities than 
the one used in our previous analysis [20]. Defining the scale or size of an ART treatment facility 
as the number of patients it treats in a given year, Figure 1 illustrates the size distribution for 
each of four levels of health care facility:  
x Level 1: Primary healthcare centres 
x Level 2: Community day centres/ Community health centres 
x Level 3: District/ regional hospitals  
x Level 4: National central hospitals/ provincial tertiary hospitals.  
 The fifth distribution, to the northeast of the other four, is of the entire combined list of all 3,558 
facilities delivering ART. 
Like the earlier incomplete size-distribution that we studied [11], the combined distribution in 
Figure 1 has an approximately constant slope in the logged variables for the first 2,000 facilities 
and then drops precipitously towards a facility size of 1. Figure 2 displays the piecewise linear 
spline fitted to the combined distribution in Figure 1, with knots at 100 and 2,000 facilities. The 
Figure 1. Empirical size distributions of 3,558 South African public facilities that 
delivered antiretroviral therapy in 2012/2013. Each point represents a facility. Axes are 
scaled to the logarithms of the variables. Source: Authors’ construction. 
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slopes of the two segments are -.32 for the first 100 facilities and -.85 for facilities ranked 
between 100 and 2000, somewhat flatter than the slopes of approximately -1 that are commonly 
observed for the rank-size distribution of cities and towns, suggesting that the size distribution of 
ART treatment facilities in South Africa has not yet matured to follow more closely that of the 
population itself. 
If all South African facilities treated the same number of patients, these size distributions would 
be flat and economies of scale would not matter for projecting treatment cost. In our clinic data, 
facilities differed in size by more than four orders of magnitude, from those that served a single 
patient to the busiest facility in the sample which served 17,081. If each facility enjoys a scale 
elasticity substantially less than unity, the impact on total cost of adding patients to the small 
facilities will be larger than adding the same number of patients to large facilities. To see how 
much difference this can make, we explore the sensitivity of cost projections to variations in how 
the additional patients are distributed by the current size of the facility and by the elasticity of 
scale that characterizes the entire system.4  
                                                          
4 In reality, the scale elasticity might vary by level of the facility, by whether it is urban or rural or by other facility 
characteristics. Given data on total annual ART treatment costs, number of patient-years of ART delivered and a 
range of other facility characteristics, in all the level 4 and a sample of 30 of each of the other levels of care, it would 
be straightforward to estimate a level-specific scale elasticity. Lacking such information, we assume the elasticity is 
constant across levels. 
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The most ambitious ART expansion modeled in this paper (UTT.UE) expands the total patient 
enrollment from the approximately 2.4 million patients currently enrolled to as many as 5 million 
patients on treatment by the year 2033. We consider two policy dimensions of the distribution of 
patients across facilities. First, we model the possible expansion of the number of ART facilities, 
from the current 3,558 up to a maximum of 7500. Secondly, we distribute the new patients 
across these facilities according to three alternative patterns. We call the three distribution 
patterns: (1) average, (2) quadratic and (3) proportional. To illustrate the difference, suppose 
that the number of facilities is held constant at 3,558 and the number of patients is to be 
increased from 2.4 million to 5 million. This would be an average increase of 815 patients per 
facility. Under the average distribution pattern, the system would add 815 patients to each 
facility, a very small additional load for the largest facility but a massive increase for the facilities 
currently serving only one patient.  
Since (5 - 2.4)/2.4 = 1.08, the increase to 5 million would be a 108% increase in the national 
number of patients. Our proportional distribution pattern would increase the patient load of each 
facility by 108%. This would mean that the largest facility, which has 17,081 patients in 2013, 
Figure 2. A piecewise-linear spline with two knots explains 94% of the variation in the size-
distribution of ART treatment facilities in South Africa in 2013. Source: Authors’ construction. 
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would expand by 18,447 patients to be serving 35,528 patients, while the facility treating only 1 
patient in 2013 would be treating only 2 patients when the country reaches maximum scale-up.  
Our quadratic distribution pattern is intermediate between the arithmetic and proportional 
patterns. For the quadratic pattern, we impose the constraint that neither the largest nor the 
smallest facility absorbs more patients, with the incremental 2.4 million patients being distributed 
across the middle of the range of facility ranks according to a quadratic relationship.  
Figure 3 displays the impact that each of these three distribution patterns would have on the 
size-rank distribution of facilities, when we hold the number of facilities constant at 3,558 and 
expand the number of patients to 5 million.  
Modeling the cost of demand generation 
Experience has shown that increasing the number of patients who effectively adhere to ART 
requires more than simply constructing facilities and making drugs available. A growing number 
of studies are analyzing the leakage in the ART care cascade with the aim of designing 
treatment programs which minimize the loss of patients at each stage in the treatment process. 
While South Africa has achieved a remarkable roll-out of ART, with the number of patients in the 
public sector rising from none in the beginning of 2004 to more than 2.4 million in 2013, these 
Figure 3. Three patterns for adding 2.9 million patients to the existing distribution or patients 
over the 3,558 facilities delivering ART in 2013. 
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gains have been achieved mainly among the sickest patients, for whom ART offers almost 
immediate health benefits. In an analysis of treatment outcomes over seven years on treatment 
in a large South African public-sector clinic, the median CD4 cell count at initiation rose from 82 
cells/microl in 2004/05 to just 114 cells/microl in 2009/10, while loss to follow-up ranged 
between 19.1% and 28.6% of each annual cohort [33]. 
By making every effort to serve the patients who most needed treatment, South Africa has 
managed so far without the need for an extensive outreach program to support patient 
adherence. We assume this will continue to be the case in the baseline scenario (Current 
guidelines, status quo). However, to the degree that an expansion scenario requires individual 
facilities to recruit patients with higher CD4 counts or who are more recalcitrant for other 
reasons, we assume that the government will have to finance outreach activities to recruit and 
then retain these additional patients. To model the anticipated cost of these outreach 
programmes, we characterize the individual facilities as supplying a service to patients who 
manifest a demand for care. Like all demand relationships, the demand for ART can be 
Figure 4.  Demand for antiretroviral therapy services.  Other things equal, the demand 
for antiretroviral services is greater when prices are lower or, in the absence of prices, 
when outreach expenditures are greater.  To achieve an ambitious target of enrolled and 
adherent patients may require large outreach expenditures especially if the elasticity is 
small.  Source: Authors’ construction. 
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expected to be small at a higher price and to increase as the price decreases. The upper half of 
Figure 4, above the horizontal axis, illustrates this “iron law of economics” with a demand curve 
plotted on axes representing the price per patient on the vertical axis and the number of patients 
on the horizontal axis. By continuing this demand curve below the horizontal axis, we extend 
this concept of the demand curve to negative prices, which we assume are spent in the form of 
a facility’s outreach costs, and might include travel vouchers or home visits or food 
supplements. We assume the outreach costs increase as the number of enrolled patients 
increases, becoming infinitely large as enrollment approaches 100% of those eligible.  
Since our model projects the growth of individual facilities, we model the outreach expenditure 
requirement for each facility as analogous to the Figure 4 depiction of demand in the entire 
country. We assume that the negligible level of outreach currently funded by the government in 
public facilities would, if continued, enable every facility’s enrollment to expand according to the 
baseline scenario. Define that status quo enrollment level in facility k, year t, as ?̃?𝑘𝑡, which is 
given by one of the three previously discussed scenarios for the extension of the number of 
clinics. Just as the outreach expenditures required to obtain 100% coverage for the entire 
country grow without limit, we assume the same is true at each facility.  
To implement these assumptions, we include the cost of demand creation for both testing and 
improved retention for every patient in addition to those in the CG.SQ scenario. For testing, we 
added the cost of a mobilisation event per tested patient, based on an ingredients cost analysis 
used in the costing of South African Provincial Strategic Implementation Plans [19]. For 
retention, in order to enable patients to present themselves for quarterly appointments at the 
ART clinic, we added an outreach cost per incremental patient which, at our assumed 
elasticities of demand, would be sufficient to attract the number of patients to that facility that 
are predicted by the given epidemiologic scenario. We calibrate these elasticities so that for a 
modest expansion the annual per-patient outreach cost would approximately equal the typical 
cost of four trips to a health center at ZAR 50 (USD 5) for an urban clinic and ZAR 30 (USD 3) 
for a rural clinic per single round trip5. Outreach cost per patient can rise to a multiple of these 
benchmark values in high coverage scenarios or in high coverage clinics. See Appendix B for 
further details on our models of supply and demand. 
Results 
Number of patients on ART 
Under the current guidelines and trends in testing, linkage to care and losses to retention 
(CG.SQ), 2.4 million adults and 202,067 children are estimated to be on treatment by mid-2016, 
and 3.4 million adults and 135,424 children by 2033 (see Table 4). If the current guidelines were 
kept, but testing, linkage to care and retention were improved to 80% each (CG.UE), these 
                                                          
5 In an analysis of the transport cost of patients accessing ART in an urban and a rural clinic in South Africa, these 
amounts would have covered the transport cost of 100% of patients in the rural clinic, and of 90% of patients in the 
urban clinic [32]. 
24 
 
numbers would increase to 3.7 million adults and 236,471 children in 2014, and 5.3 million 
adults and 103,789 children in 2033. 
Under all other uniform expansion (UE) scenarios, there are more patients expected to be on 
treatment by mid-2016, and less by mid-2033, than under CG.UE; there is in fact an inverse 
relationship between the number of patients on treatment by mid-2016 and those on treatment 
by mid-2033 for all scenarios. This result illustrates the assumed prevention benefits of ART, as 
higher eligibility in early years reduces HIV incidence and thus leads to fewer eligible patients in 
later years 
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Table 4: Number of patients on ART by scenario 
Scenario 
Adults on 
ART by mid-
2016 
Children on 
ART by mid-
2016 
Adults on 
ART by mid-
2033 
Children on 
ART by mid-
2033 
Current guidelines (CG)     
Status quo (SQ) 2,401,552 202,067 3,402,879 135,424 
Uniform expansion (UE) 3,724,236 236,471 5,266,077 103,789 
Universal test and treat (UTT)     
Status quo (SQ) 2,770,414 201,347 3,613,720 99,467 
Uniform expansion (UE) 4,431,985 226,155 4,947,584 52,651 
Eligibility <500 (500)      
Status quo (SQ) 2,697,173 201,570 3,591,006 107,837 
Uniform expansion (UE) 4,375,441 228,299 4,998,933 57,649 
Discordant couples (DC)      
Status quo (SQ) 2,386,998 204,281 3,391,194 136,638 
Prioritised expansion (PE) 3,309,333 199,201 4,879,992 81,912 
Uniform expansion (UE) 3,868,680 234,240 5,137,060 82,751 
Pregnant women (PW)     
Status quo (SQ) 2,441,042 201,883 3,413,530 125,253 
Prioritised expansion (PE) 2,508,171 199,617 3,466,497 109,445 
Uniform expansion (UE) 3,789,507 229,648 5,213,924 77,725 
 
Trend of undiscounted HIV-related cost over time 
Unlike in the first analysis of universal test and treat scenarios[4], none of the scenarios in our 
analysis is cost-saving over 20 years, though most of the status quo (SQ) sub-scenarios might 
be cost-saving over longer time periods. This can be seen from Figure 5 (Panel a. and b.), 
which tracks the undiscounted cost of HIV-related care for people on or off ART (Panel a.) and 
on ART only (Panel b.), by year: The cost curves in most scenarios flatten towards the end of 
the projection period (both panels), and the cost curves of all HIV-related care of most of the SQ 
scenarios (whose incremental cost over the baseline scenario per year is very small throughout) 
cross the curve of the baseline scenario (CG.SQ) in the last years of the projection period 
(Panel a.), suggesting cost savings in the annual cost from the year in which the lines cross 
onwards. The same is true for the cost of the PW.PE scenario. 
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Figure 5: Total undiscounted cost per year for all HIV-related care (Panel a.) and for 
patients on ART only (Panel b.) 
For planning and budgeting purposes, Appendix C gives the undiscounted annual cost for each 
of the years 2014-2033 as well as the current mid-term expenditure framework (MTEF) of 2014-
2016 for each scenario. 
Total HIV-related cost 
At the discount rate of 3%, the total cost over 20 years for the current guidelines at status quo 
(CG.SQ) is expected to be close to USD 36 billion (Table 5 and Figure 6), equivalent to an 
annual payment of US$2.4 billion. For reference, the discounted cost for the current mid-term 
expenditure framework of 2014-2016 is USD 3.6 billion, or about US$1.2 billion per year. Figure 
6 displays the breakdown of total cost under the central assumptions used in this paper. The 
scenarios are ordered by recruitment sub-scenario (from SQ to PE to UE) and then by eligibility 
scenario in order to highlight that, regardless of eligibility criterion, the status quo scenarios are 
less costly and the uniform expansion scenarios most costly.  
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Figure 6 displays other patterns worth noting. The large contribution of non-ART inpatient and 
outpatient services under the SQ scenarios is greatly reduced under the UE scenarios, but its 
place is filled by the large additional expenditure for testing. The two parts of ART costs we 
have assumed to be unrelated to the scale of a facility’s work load, the cost of ARVs and labs, 
rise with the number of patients on treatment, as does inpatient cost for patients on ART. The 
component that rises the most is the cost of outreach. Under our central assumption set, we set 
the elasticities of urban and rural demand to equal respectively 0.1 and 0.5. We assume cost of 
outreach to be zero in the baseline CG.SQ scenario and to barely appear at all under the other 
SQ or the PE scenarios. This is because none of these scenarios is projected to require a large 
percentage increase in patients. However, all five of the UE scenarios as well as the DC.PE 
scenario must greatly increase patient recruitment, and therefore incur demand creation costs 
determined by the assumed testing costs and demand elasticities.  
 
Figure 6. Total HIV-related health care costs and its components in South Africa 2014-33 
(discount rate 3%) 
 
Cost effectiveness 
As shown in Table 5, improving testing, linkage to care and retention under the current eligibility 
in the CG.UE scenario would increase total cost over 20 years by USD 14.6 billion to a total of 
USD 50.5 billion and would reduce new infections by close to 50% to 1.9 million. This results in 
a cost per infection averted of USD 7,559, the highest cost per infection averted of all scenarios, 
including all other uniform expansion sub-scenarios. 
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The most cost-effective option in terms of cost per infection averted is to expand ART eligibility 
to pregnant women, either while maintaining the status quo for linkage and retention (PW.SQ) 
or while improving their linkage and retention and maintaining the status quo for everyone else 
(PW.PE). On the other hand, expanding eligibility for discordant couples, either as prioritized or 
as uniform expansion (DC.PE or DC.SQ), is the least cost-effective option of all PE or SQ 
scenarios.  
When maintaining the current status quo for testing, linkage to care and retention, expanding 
eligibility to discordant couples or pregnant women would have little effect on either cost or 
infections averted. This is because coverage of ART is already high in pregnant women 
compared to the general population, and current levels of partner testing are relatively low, so 
that few additional people would be reached by expanding guidelines to these groups unless 
effort is made to also encourage testing and linkage to care. Expansion of eligibility guidelines to 
include persons with a CD4 cell count of <500 cells/microl or all infected individuals (UTT) would 
significantly increase both cost and infections averted. Of these two strategies, universal test 
and treat would be associated with about 5% lower cost per infection averted and both are 
about 30% more cost-effective than uniformly expanding under current eligibility guidelines. 
Table 5. Cost, infections averted and cost effectiveness by scenario 
          Incremental 
  Total cost Total new Incremental   cost per HIV 
  2014-2033 infections cost Infections infection 
  [billion 2014-2033 [billion averted averted 
Scenario 2013 USD] [millions] 2013 USD] [millions] [2013 USD] 
Current Guidelines (CG):     
 Status quo (SQ) 36.0 4.3 comparator comparator comparator 
 Uniform 
expansion (UE) 
50.5 2.3 14.6 1.9 7,559 
Universal test and treat (UTT):     
 Status quo (SQ) 37.6 3.7 1.6 0.6 2,671 
 Uniform expansion 
(UE) 
49.6 1.7 13.6 2.6 5,283 
Eligibility < 500 
(500): 
     
 Status quo (SQ) 37.3 3.8 1.3 0.5 2,832 
 Uniform expansion 
(UE) 
49.8 1.8 13.9 2.5 5,544 
Discordant couples 
(DC): 
     
 Status quo (SQ) 35.9 4.3 -0.1 0.0 See note* 
 Prioritised 
expansion (PE) 
44.9 2.9 9.0 1.3 6,671 
 Uniform expansion 
(UE) 
50.5 2.1 14.5 2.2 6,723 
Pregnant women 
(PW): 
     
 Status quo (SQ) 36.1 4.2 0.2 0.1 1,692 
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 Prioritised 
expansion (PE) 
36.4 4.0 0.4 0.2 1,979 
 Uniform expansion 
(UE) 
50.3 2.2 14.4 2.0 7,009 
Note: This table uses the central assumptions. Supply side: Sigma = 0.8, Kmax = 6000, Scale-up pattern = 
Quadratic, Demand elasticities: Urban = 0.1, Rural = 0.5. Discount rate: 3%. 
*Incremental costs and effectiveness are computed in comparison to the CG.SQ scenario. The effectiveness of the 
DC.SQ scenario is too close to those of the comparator CG.SQ scenario for the cost-effectiveness result to be 
meaningful. 
  
The cost-effectiveness ranking of the policy options is similar when effectiveness is measured 
by DALYs saved instead of by HIV infection averted (Table 6 and Figure 7). Since averting an 
HIV infection averts several years of disability-adjusted life, it is not surprising that the cost per 
averted HIV infection is higher than the cost per DALY for the same intervention. The cost per 
averted DALY can be compared to the value of the typical person’s healthy year, while the cost 
per averted HIV infection can be compared to the value of the person’s life expectancy.6 
As before, the most expensive and least cost-effective option is the uniform expansion of the 
current guidelines, which we estimate to cost $1,015 per DALY saved. Among the five uniform 
expansion scenarios, the cost-effectiveness advantage of the most ambitious of these, the less 
than 500 and the UTT, is less pronounced by the DALY metric than by the infection averted 
metric. Both are about 10% more cost-effective than the uniform expansion under current 
eligibility guidelines.  
                                                          
6 Because the projection horizon in this exercise is limited to 20 years, there is insufficient time to observe all the 
DALY benefits of averting an HIV infection.  For any given expansion policy and cost assumptions, a longer planning 
horizon should reveal a larger ratio of DALYs averted to infections averted. 
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Figure 7. Cost per HIV infection and DALY averted for 11 scenarios compared to the 
current guidelines status quo scenario (discount rate 3%).7 
  
                                                          
7 The negative value associated with the discordant couple (DC) scenarios in Figure 7 occur because the 
effectiveness of this scenario is less than the effectiveness of the other scenarios and the costs are larger. The 
implausible figure of -$62,859. occurs because the number of infections averted is very slightly less than in the 
baseline scenario, so the denominator of the cost effectiveness ratio is a negative number close to zero. 
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Table 6: Disability-adjusted life years (DALYs) averted and cost utility by scenario 
 (discount rate = 3%) 
 
Scenario 
Total cost 2014-
2033 [billion 
2013 USD] 
Total DALYs 
2014-2033 
[millions] 
Incremental 
cost [billion 
2013 USD] 
DALYs 
averted 
[millions] 
Incremental cost 
per DALY averted 
[2013 USD] 
Current guidelines (CG)      
 Status quo (SQ) 36.0 592.1 comparator comparator comparator 
 Uniform expansion (UE) 50.5 606.4 14.6 14.4 1,015 
Universal test and treat (UTT)      
 Status quo (SQ) 37.6 594.2 1.6 2.1 759 
 Uniform expansion (UE) 49.6 607.3 13.6 15.2 895 
Eligibility < 500 (500)      
 Status quo (SQ) 37.3 594.0 1.3 1.9 701 
 Uniform expansion (UE) 49.8 607.2 13.9 15.1 914 
Discordant couples (DC)      
 Status quo (SQ) 35.9 591.6 -0.1 -0.4 216 
 Prioritised expansion (PE) 44.9 602.4 9.0 10.4 866 
 Uniform expansion (UE) 50.5 606.6 14.5 14.6 995 
Pregnant women (PW)      
 Status quo (SQ) 36.1 592.3 0.2 0.2 865 
 Prioritised expansion (PE) 36.4 592.8 0.4 0.8 593 
 Uniform expansion (UE) 50.3 606.5 14.4 14.5 992 
Note: Supply side: Sigma = 0.8, Kmax = 6000, Scale-up pattern = Quadratic, Demand elasticities: Urban = 0.1, Rural 
= 0.5 
 
Figure 8 Panels a. to d. give a graphical representation of these results for central values of the 
behavioral supply- and demand-side parameters. As has become the convention for displaying 
incremental cost-effectiveness ratios (ICERs), these charts display the 20-year cost of each 
scenario relative to the baseline scenario, status quo scenario on the vertical axis and the 20-
year utility relative to same counterfactual on the horizontal axis. Thus scenarios represented by 
points with high costs and low utility will be closer to the vertical axis, while those with low costs 
relative to their utility will be close to the horizontal axis. The distance of a point from the origin 
represents the magnitude of the costs and utility in comparison with the counterfactual in which 
the country remains on its present course.  
Panel a. of Figure 8 displays the cost-effectiveness of three scenarios relative to CG.SQ 
scenario. The uniform expansion of the current guidelines (eligibility threshold at a CD4 cell 
count of 350) will have the greatest cost but produce only a modest reduction in DALYs, so that 
its cost effectiveness, represented by the steep slope of the ray connecting the point CG.UE to 
the origin, is USD 7,559 per HIV infection averted over the 20 years. On cost-effectiveness 
grounds, this scenario is the least attractive option we analyse. It is dominated by other 
scenarios not only under this set of parameters, but under all the parameter combinations we 
32 
 
have explored. In contrast, Panel a. also displays two universal test and treat (UTT) policies, 
both of which are more cost-effective than the CG.UE option. In comparison to scenario CG.SQ, 
applying the status quo recruitment policies with the UTT eligibility criteria will purchase 600,000 
averted HIV infections at a cost of only USD 2,671 per averted infection. Energetically extending 
the same UTT eligibility criterion with the uniform expansion of service and recruitment efforts 
prevents additional infections at a cost of USD 6,088 per infection averted, which is less than 
half as cost-effective as moving to UTT.SQ, but still more cost-effective than CG.UE. 
Panel b. of Figure 8 shows the results for expanding the eligibility criterion to a CD4 count less 
than 500 cells/microl, an intermediate policy option between the current guidelines and the 
universal test and treat options depicted in Panel a. While the 500 CD4 count threshold option 
performs very similarly to the UTT option, note that it is estimated to be a slightly more 
expensive way for the government to “buy” these averted infections. This is because it achieves 
fewer prevention benefits in the outer years than does the UTT option, though the difference as 
simulated in our model is small.  
Panels c of Figure 8 shows that prioritized expansion to discordant couples averts 1.3 million 
HIV additional infections at an additional cost of USD 9 billion, for a cost-effectiveness of $6,747 
per averted infection. For this discordant couple policy option, the more vigorous UE recruitment 
strategy is almost equally cost-effective, costing $6,809 per additional infection averted. Panel d 
shows that the cost-effectiveness of prioritized recruitment of pregnant women, at less than 
$2,200 per HIV infection averted, compares favorably with that of universal test and treat under 
the status quo recruitment strategy ($2,671 in panel a). However the PW PE scenario buys only 
a third as many additional averted HIV infections as the CG SQ strategy (200,000 as opposed 
to 600,000) and further effort on the pregnant women policy to uniform expansion is unattractive 
since it’s cost per HIV infection averted is as high as that of uniform expansion under the current 
guidelines. 
A remarkable feature of the cost-effectiveness calculations displayed in Figure 8 is the kinked 
shape in Panels a, b and d. This shape means that initial expansion can be a good buy, but 
subsequent expansion to a UE scenario, while achieving important health benefits, is less cost-
effective. This pattern of rising marginal costs as an infectious disease control program nears its 
goal of disease elimination is familiar from the smallpox and polio eradication campaigns.  
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Figure 8. Incremental cost effectiveness of expansion strategies for adult ART, 2014-2033 
 
 
Cost benefit  
The cost-benefit ratio, calculated as (incremental cost - cost of orphanhood averted) / value of 
gained productivity, is given in Table 7. A value between 0 and 1 means that the value gained 
by the ART program is higher than the net cost of implementing the program. In all scenarios, 
there are fewer orphans compared to the current guidelines scenario; in all but the DC.SQ and 
the PW.SQ scenarios, productivity is gained, especially under the uniform expansion scenarios. 
As a result, the cost-benefit ratio is highly favourable for all scenarios, with values between 0.08 
(DC.PE) and 0.32 (UTT.SQ). 
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Table 7. Cost of orphanhood, value of productivity, and cost benefit by scenario 
(discount rate = 3%) 
 
Scenario 
Total cost 
2014-2033 
[billion 
2013 USD] 
Orphanhood 
cost 
2014-2033 
[billion 2013 
USD] 
Value of 
productivity 
[billion 2013 
USD]  
Incremental 
cost [billion 
2013 USD] 
Orphanhood 
cost 
averted 
[billion 2013 
USD] 
Productivity 
gained 
[billion 2013 
USD] 
Incremental 
cost-benefit 
ratio 
Current guidelines (CG)        
 Status quo (SQ) 36.0 0.328 836 comparator comparator comparator comparator 
 Uniform expansion (UE) 50.5 0.280 979 14.5 0.049 143.0 0.10 
Universal test and treat (UTT)        
 Status quo (SQ) 37.6 0.317 841 1.6 0.012 5.2 0.32 
 Uniform expansion (UE) 49.6 0.268 926 13.6 0.061 89.9 0.15 
Eligibility < 500 (500)        
 Status quo (SQ) 37.3 0.319 846 1.3 0.010 10.8 0.13 
 Uniform expansion (UE) 49.8 0.270 933 13.8 0.059 97.7 0.14 
Discordant couples (DC)        
 Status quo (SQ) 35.9 0.327 832 -0.1 0.002 -3.6 0.03 
 Prioritised expansion (PE) 44.9 0.283 944 8.9 0.046 108.1 0.08 
 Uniform expansion (UE) 50.5 0.275 960 14.5 0.054 124.7 0.12 
Pregnant women (PW)        
 Status quo (SQ) 36.1 0.325 835 0.1 0.004 -0.6 -0.10 
 Prioritised expansion (PE) 36.4 0.305 840 0.4 0.024 4.0 0.09 
 Uniform expansion (UE) 50.3 0.272 973 14.3 0.056 136.9 0.10 
 
Sensitivity analysis 
We did a total of 13,824 computations of the model, 6,912 for each of two assumptions about 
the patients who would require outreach cost. We always assumed that outreach costs would 
be paid to all patients in excess of those who would seek care each future year under the 
CG.SQ scenarios. However, when the eligibility criterion is expanded from a CD4 count of 350 
to one of 500 or to all HIV positives, a given facility will eventually have fewer patients starting at 
low CD4 counts because it has more starting earlier, at higher CD4 counts. Thus the net 
increase in patients at that facility will be smaller than the increase in patients at higher starting 
CD4 counts. A simple assumption is that patients who would have eventually started treatment 
without outreach costs at a CD4 count of 350, will also be willing to start earlier without outreach 
costs. In this case only patients who would never have come under the current guidelines will 
require outreach expenditure. Alternatively outreach expenditure may be required to induce a 
patient with a high CD4 count to start treatment earlier even if that same patient would have 
started later without that inducement. In this second case, outreach costs must be paid to 
increase the number of patients in any CD4 category. To capture these two possibilities, for half 
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the scenarios, we defined patients requiring outreach expenditure to be those in excess of the 
CG SQ scenario for the facility as a whole; for the other half, we calculated the increment 
between the two scenarios in the number of patients in each CD4 category, and applied 
outreach costs to those patients in health states with positive increments only.  
For each of these two assumptions about which patients would require outreach expenditure, 
we computed 12 scenarios x 4 discount rates x 3 scale elasticities x 4 patient distribution 
patterns x 12 elasticity of demand combinations. Choosing one scenario and discount rate 
combination, the cost effective UTT.SQ scenario evaluated at a discount rate of 3%, the 144 
supply and demand side parameter combinations are displayed in Table 8. Note that the cost-
effectiveness varies from USD 1,471 to USD 10,434 per HIV infection averted across these 
combinations, with most of the variation due to the demand side parameters. 
Table 8. Cost of the universal test and treat, with status quo expansion, scenario per incremental HIV 
infection averted relative to the current guidelines, status quo scenario (discount rate = 3%) 
Elasticities of 
demand 
Build-out scenario and elasticity of scale 
Proportional to 4,500 Quadratic to 4,500 Quadratic to 6,000 Quadratic to 7,500 
Rural Urban 0.6 0.8 1 0.6 0.8 1 0.6 0.8 1 0.6 0.8 1 
0.05              
 0.05 10,050 10,230 10,434 7,840 7,911 7,905 6,282 6,252 6,146 5,459 5,342 5,160 
 0.1 7,685 7,865 8,069 6,870 6,941 6,934 5,513 5,482 5,376 4,792 4,675 4,493 
0.1              
 0.05 7,899 8,079 8,283 5,602 5,674 5,667 4,720 4,690 4,584 4,284 4,167 3,985 
 0.1 5,534 5,714 5,918 4,632 4,703 4,696 3,951 3,920 3,814 3,617 3,500 3,318 
 0.5 3,643 3,823 4,027 3,856 3,927 3,920 3,335 3,304 3,198 3,083 2,966 2,784 
0.5              
 0.05 6,178 6,358 6,562 3,812 3,883 3,877 3,471 3,440 3,334 3,344 3,227 3,045 
 0.1 3,814 3,994 4,198 2,842 2,913 2,906 2,701 2,671* 2,564 2,677 2,560 2,378 
 0.5 1,922 2,102 2,306 2,065 2,137 2,130 2,085 2,055 1,949 2,143 2,026 1,844 
1              
 0.05 5,963 6,143 6,347 3,588 3,660 3,653 3,314 3,284 3,178 3,227 3,109 2,927 
 0.1 3,599 3,779 3,983 2,618 2,689 2,682 2,545 2,514 2,408 2,560 2,442 2,260 
 0.5 1,707 1,887 2,091 1,842 1,913 1,906 1,929 1,899 1,792 2,026 1,908 1,727 
 1 1,471 1,651 1,855 1,745 1,816 1,809 1,852 1,822 1,715 1,959 1,842 1,660 
Note: Discount rate: 3%; Outreach costs paid to additional patients in each CD4 category.  
*The bolded value of $2,671 in the seventh row and eighth column of this table corresponds to our central 
assumptions of demand and supply elasticities and assumed build out policy and appears in Table 5 and 
in Panel a of Figure 8. 
Our sensitivity analysis can also be used to explore whether the kinked shape of the expansion 
path is due to the assumptions we have incorporated into our model of the supply and demand-
side determinants of scale-up cost. Figures 9 and 10 show the sensitivity of the shape of the 
incremental expansion path for the UTT strategy to variations around our central assumptions of 
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the supply and the demand behavioral elasticities respectively. These figures show that the 
distinctive concave kink in these expansion paths is robust to these variations.  
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Figure 9 shows that the proportional build-out policy of squeezing new patients into the largest 
facilities doubles the cost per HIV infection averted compared to any of the quadratic expansion 
policies, with the least expensive being those which expand to the largest number of facilities. 
This is because the additional outreach cost at the large facilities outweighs the savings from 
scale economies. 
 
Figure 9. Sensitivity of the cost effectiveness of the UTT scenario to alternative supply-side 
assumptions 
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Figure 10 shows that varying the elasticity of demand for the rural population from 1 down to .05 
can also double the cost per HIV infection averted and accentuate the kink in the expansion 
curve. The determinants of the demand for antiretroviral therapy for patients with high CD4 
counts are not yet well known. If patients are relatively unresponsive to demand generation 
expenditures as captured here by small demand elasticities, the cost of achieving sufficiently 
high treatment coverage among recently infected individuals to generate HIV prevention 
benefits will equal exceed the highest of our estimates.  
 
Figure 10. Sensitivity of the cost-effectiveness of the UTT scenario to alternative demand-side 
assumptions 
 
Finally Figure 11 extends the sensitivity analysis to 1,728 parameter combinations for each of 
the four discount rates and shows that, while the cost per DALY averted ranges widely within 
this parameter space, from as low as a few dollars to as high as USD10,000, the distinctive 
shape remains. Rather than demonstrating the benefits of increasing treatment coverage 
beyond the tipping point, our costing of these scenarios suggests that their cost effectiveness 
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will degrade with scale-up, rather than improving as one might have expected. We return to this 
point in the Conclusions section. 
Figure 11. Results of sensitivity analysis involving 1,728 parameter combinations for each of the 
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four discount rates. *An “expansion path” is defined as the sequence of cost and utility combinations 
which start from CG.SQ and proceed step-by-step to a) supplement current eligibility by adding specific 
population X, but with current patterns of testing and service uptake (scenario X.SQ); b) expanding 
testing and service provision to provide prioritized access for population X (scenario X.PE) (where 
available); and c) further expand testing and service provision to provide uniform access to 80% of the 
population (scenario X.UE). The cost per HIV infection averted is undefined for the DC SQ scenario. 
 
 
 
Some additional insight into the sources of variation in cost-effectiveness in this model can be 
gleaned from a chart showing the contribution of each of the ART components to the cost-
effectiveness analysis. The height of each segment of each bar in Figure 12 is computed by 
dividing the cost associated with that component from the corresponding Figure 6 by the 
number of DALYs averted. All of the resulting ratios are positive except that for DC.SQ. 
 
41 
 
Figure 12. Net cost per HIV infection averted and its components for 11 scenarios 
(discount rate 3%) 
Comparison with previous analyses of ART expansion 
As mentioned in the Introduction, this analysis is an extension of and addition to the previously 
mentioned 12-model comparison project [12] that was instrumental in advising the World Health 
Organization during the guideline revision process for the 2013 ART guidelines. The major 
change we introduced in this analysis was the treatment of part of the cost of treatment 
provision as a function of scale, and modelling the cost of increasing patient demand for ART to 
the required levels for 80% testing uptake, linkage to care, and retention in care. There are a 
number of other differences between the two analyses with regards to cost and outcomes. 
First, all unit costs used in the 12-model analysis were the result of the synthesis of a number of 
separate cost estimates from the literature, using specialized software, of which the average 
cost from the National ART Cost Model (NACM) used in this analysis was only one input. Since 
most prices relevant to ART provision in South Africa, especially those of ARV drugs, have 
decreased dramatically since 2010 [13, 14] and the inputs for the evidence synthesis included a 
number of older estimates, the input costs used in the 12-model analysis were higher 
throughout. Furthermore, the distribution of patients into first- and second-line drug regimens 
was treated as a constant in the 12-model analysis, whereas it is based on the health-state 
transition matrix contained in the NACM in our analysis. Second, the 12-model analysis adds 
the cost of programme management (at 50% of non-ARV cost) and supply-chain management 
(at 20% of ARV drug costs), with the values of these mark-ups based on expert opinion. In our 
analysis, the cost of supply chain management is included in the ARV drug costs, and 
management cost, which have never been quantified for the South African ART programme, are 
excluded. Third, we add the cost of mobilization for every HIV-positive person being tested, 
while the 12-model analysis only allowed additional outreach costs for testing individuals from 
specific sub-populations (female sex workers, men who have sex with men, and intravenous 
drug users). Fourth, we allow the cost of ART provision at the level of the clinic to decrease with 
the scale of each clinic. Fifth, we add the cost of a transport voucher per incremental patient on 
ART over the current guidelines (status quo) scenario, as a proxy for increasing demand to the 
higher coverage levels assumed in all other scenarios.  
Eaton et al [12] concluded that, “[i]n South Africa, the cost per DALY averted of extending 
eligibility for antiretroviral therapy to adult patients with CD4 counts of 500 cells per μL or less 
ranged from $237 to $1691 per DALY averted compared with 2010 guidelines.” Our estimate is 
that this policy would cost $914 per DALY averted under our central assumptions, but could 
range from a low of $658 to a high of $3,706 per DALY averted depending on the elasticities of 
demand and supply and the national build-out policy. The 12-model analysis’ findings that all 
expansion strategies are cost-effective for South Africa as measured against international 
thresholds still holds in our analysis for our central assumptions, and the ranking of expansion 
options by their incremental cost effectiveness is similar between the two analyses. 
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Conclusions 
We combined the outputs of an epidemiological and a cost model of the HIV epidemic in South 
Africa to calculate the incremental cost effectiveness of a range of eligibility expansion 
strategies over current guidelines. Using the existing ART programme in South Africa as a 
baseline, we model the incremental cost per infection or DALY averted of each of 11 different 
policy alternatives for its expansion. In terms of total cost, all scenarios that maintain current 
trends in testing coverage, linkage to care, and retention in care (‘status quo’) have a very 
similar cost of around 36 billion USD over 20 years, while all scenarios that, for any given 
eligibility, assume uniform expansion of testing, linkage and retention for the entire population of 
eligible people (‘uniform expansion’), have a total cost over 20 years of 50 billion USD. Within 
these, expanding eligibility to discordant couples (at current testing and linkage levels) and all 
pregnant women (at current and improved testing and linkage levels) are the least costly 
options, followed by expanding eligibility to all patients with CD4 cell counts < 500 cells/microl 
and Universal Testing and Treatment, both at the current level of testing and linkage.  
The incremental cost per infection averted is comparable between all ‘status quo’ scenarios, 
with the prioritisation of pregnant women being the most cost-effective scenario, though it has 
little overall impact because HIV testing rates are already high amongst pregnant women due to 
high coverage of antenatal care in South Africa. All ‘uniform expansion’ scenarios have both 
greater cost and greater impact, and are more costly per infection averted. The same pattern 
emerges in terms of cost per DALY averted, although the differences across the scenarios are 
exaggerated as a result of the CD4 cell count-dependency of the disability weights for people 
not on ART.  
Under both cost-effectiveness metrics however, cost per infection averted and cost per DALY 
averted, the uniform expansion of the current guidelines has the highest cost per outcome of all 
scenarios; if the political decision were to expand services to all eligible patients, defining 
eligibility as ‘all patients with CD4 cell counts < 500 cells/microl’ or simply as ‘all HIV-positive 
patients’ saves money over 20 years on simply expanding coverage to all patients eligible under 
the current eligibility threshold of 350 cells/ microl. 
Because the scenarios are graduated in the number of people they cover, we can analyse the 
incremental cost-effectiveness in terms of cost per DALY averted along a hypothetical 
expansion path that would result from adopting a modest version of an eligibility strategy and 
then expanding recruitment efforts from status quo, through prioritized expansion to uniform 
expansion. This exercise reveals that the incremental cost effectiveness is quite favorable for 
small expansions, averting an HIV infection at less than $3,000 and a DALY at less than USD 
800 under our central assumptions. However, in most scenarios and robust to a wide number of 
alternative assumptions, the incremental cost-effectiveness ratio of scaling all the way to the 
uniform expansion scenario is from two to five times more expensive per infection or DALY 
averted. This finding leads us to wonder how the ICER would behave if we had assumed even 
higher levels of recruitment and utilization, i.e., 95% instead of 80%. Would the difficulties of 
attracting these last patients prove prohibitively costly driving up the ICER? Or would an even 
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more aggressive scale-up, although incurring higher costs per patient reached, also achieve 
even greater prevention benefits and thus yield more optimistic cost-effectiveness estimates? 
Ultimately there is no substitute for empirical evidence production and outreach cost. How many 
unidentified cases of HIV never come to the center at all or come when it’s too late? And how 
much will it cost to attract these missing patients to seek care and persist in adhering? On the 
production side, countries should routinely report not only the number of patients on treatment, 
but their distribution across facilities, so projections can incorporate economies of scale and 
spatial distribution. Universal coverage will also require detailed country-specific estimates for 
the elasticities of demand that we model here.  
Furthermore, instead of subsuming all demand enhancing interventions into a single outreach 
cost, a more useful model of demand would distinguish among elasticities with respect to travel 
vouchers, distance from home to facility, provider attitudes as well as characteristics of the 
patient, such as their CD4 cell count, income and education. Incorporating such a fully specified 
demand model into a AIDS treatment projection model has the advantage of enabling the 
analysis of the cost-effectiveness of multiple policy instruments. As knowledge accumulates 
about the influence of such policies, census and survey data on the exact geospatial locations 
of HIV infection can be used to build granular spatial models of demand which would enable 
policymakers to optimize the placement of new facility construction and outreach services. 
These tools would help governments plan their own policies and help them in the increasingly 
competitive and demanding process of preparing investment cases to compete successfully for 
donor support.  
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Appendix A:  
Model Description EMOD-HIV v0.8 
All epidemiological simulations were performed using EMOD-HIV v0.8, a population model of 
HIV transmission calibrated to the national-level epidemic in South Africa(1). It builds upon 
EMOD-HIV v0.7, an individual-based stochastic simulation of sexual and vertical HIV 
transmission in a generalized epidemic setting. We have previously published the 
epidemiological, behavioral, and transmission parameters of EMOD-HIV v0.7(2).  
The model simulates transmission between individuals who are paired in partnerships. 
Relationships are dynamically formed and dissolved at age- and gender-dependent rates 
governed by a pair formation algorithm (PFA), which has been described in mathematical 
detail(3). Briefly, the PFA establishes age- dependent rates of relationship formation necessary 
to reproduce the age patterns of relationships reported in a longitudinal household survey 
conducted in KwaZulu-Natal, South Africa (4). The PFA then fixes these rates in order to allow 
the age pattern of partnerships to vary with future demographic changes. 
Transmission within partnerships is simulated at the level of individual coital contacts. The 
model accounts for “coital dilution,” i.e., less frequent contacts when either partner is engaged in 
additional concurrent partnerships. The transmission rate per coital act depends on disease 
stage, condom usage, STI status, circumcision status, and other factors described 
previously(2).  
EMOD-HIV v0.8 includes the time-dependent scale-up of HIV treatment by simulating the 
“cascade of care” (Figure S1) in which testing rates, linkage rates, and eligibility criteria were 
allowed to vary over time according to the scale-up of testing and treatment in South Africa. 
Testing and linkage rates were also allowed to vary by gender to fit the number on treatment by 
gender and year(5). 
HIV testing in EMOD-HIV can occur as a result of voluntary testing by sexually active 
adolescents and adults, antenatal testing at 14 weeks gestation, infant HIV RNA testing, 
couples testing in which seropositive individuals recruit regular partners to test at a follow-up 
visit, or symptomatic testing at CD4 counts below 200 cells/µL. 
 
Rates of voluntary testing and counseling vary by calendar year and by age, with some 
individuals beginning regular testing shortly after sexual debut, and others beginning later in life. 
The rates were set to match the self-reported proportion of individuals ever tested and tested in 
the last year according to national-level survey data(6–8), and adjusted to match rates of ART 
initiation(5) and CD4 counts at ART enrollment(9, 10). For males, the probability of beginning 
regular testing at debut is 0.5% during the early epidemic, and grows to 25% in the present year 
and onward. The most rapid growth in at-debut testing occurs in 2000. The annual rate of 
beginning regular testing after debut also grows over time, from zero in 1998 to 4% in 2003 and 
27% in 2009 and onward. For females, all these rates are increased by 30%. Unlike other forms 
of testing, voluntary testing can only produce one positive test result. It is assumed that 
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individuals who test positive and subsequently fail to link or drop out of pre-ART or ART care will 
not resume voluntary testing after loss to follow-up. However, these individuals can re-test and 
link to care via antenatal testing, couples testing, or symptomatic testing. 
 
 
 
Antenatal testing was assumed to occur at 14 weeks gestation and to vary by calendar year. 
The rates were estimated by multiplying the time-variable coverage of antenatal services by the 
time-variable rate of HIV testing and counseling in antenatal clinics(11–13). This ANC testing 
Figure S1. Illustration of the “cascade of care” modeled in EMOD-HIV v0.8. Individuals enter 
the cascade by receiving a diagnostic test motivated by voluntary, antenatal, couples, infant, or 
symptomatic testing. Individuals must not receive false negative test (98%) and must return for a 
CD4 count result (59% without an expanded access intervention) in order to be evaluated for 
treatment eligibility. Ineligible individuals may link to pre-ART care and return for semiannual CD4 
monitoring, while eligible individuals may link to ART, with probabilities that change according to 
gender and over the course of ART scale-up. Eligibility guidelines also change in accordance to 
2004, 2010, and 2011 changes in treatment guidelines in South Africa, and may change in 2014 to 
simulate a guideline change intervention. 
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probability increased from 0% in 2000 to 7% in 2001, 58% in 2002, and 85% in 2006, with linear 
interpolation between these time points. 
Couples testing was assumed to occur after an individual tests, receives a CD4 count, is 
deemed not yet eligible for ART, and successfully links to pre-ART care. Pre-ART monitoring 
visits are assumed to occur every six months. If the individual has an active sex partner at the 
time of the pre-ART visit, the probability of bringing the partner for HIV testing is assumed to be 
10%. If the individual has multiple partners, the longest-standing partner is brought for testing. 
The partner receives HIV testing and counseling at this time, and thus may enter the treatment 
cascade via the couples testing modality. Because of low rates of linkage to pre-ART care and 
the low baseline rate of partner recruitment, partner testing is not a significant source of ART 
initiations at baseline. 
 
Finally, individuals receive an HIV test when symptomatic, which is assumed to occur at a CD4 
count below 200 cells/µL, chosen randomly between 200 and 100 cells/µL for some individuals 
and between 100 and 0 cells/µL for other individuals. The proportion who test due to AIDS-
related symptoms above versus below 100 cells/µL was adjusted to match the number of 
individuals on treatment over time(5) and CD4 counts at ART initiation(9, 10). The CD4 count at 
symptomatic presentation is assumed to be between 200 and 100 cells/µL for 40% of males and 
50% of females, and below 100 cells/µL for 60% of males and 50% of females. 
 
Only 80% of the population could access all four modes of testing (voluntary, antenatal, 
couples, and symptomatic). This was the same 80% of the population that was deemed to be 
accessible by improvements in testing and linkage rates in the expanded access scenarios. The 
remaining 20% received only antenatal and AIDS-symptomatic testing, and were not affected by 
health care improvements in the expanded access scenarios. 
 
Two percent of individuals receive a false negative diagnostic test(14, 15) and therefore do not 
link to care, but could potentially re-test at a future time. After receiving a positive HIV test, a 
proportion of individuals return for a CD4 result and determination of ART eligibility. The 
probability of doing so is 59% at baseline(16), increasing to 100% in 2014 in scenarios with 
expanded access to care. Changes in guidelines were assumed to have no effect on the 
proportion retained in this stage of the cascade, even in scenarios where eligibility was 
independent of CD4 count.  
 
EMOD-HIV v0.8 accounts for South African national guideline changes in 2004, 2010, and 
2011, as well as a possible guideline change in 2014 depending on the scenario. Eligible 
individuals may link to ART; ineligible individuals may link to pre-ART. The probabilities of 
linking to pre-ART and ART were adjusted along with other parameters to match the total 
number enrolled in ART over time(5) and CD4 counts at ART initiation(9, 10). 
 
The probability of returning for each subsequent 6-monthly pre-ART monitoring visit was 
assumed to be the same as the pre-ART linkage probability. Retention time on ART is 
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exponentially distributed with a mean of 10 years, with a dropout probability of 9.5% in the first 
year.  
 
The model was calibrated to HIV prevalence by gender, age, and year; proportion ever tested 
and recently tested by gender, age, year; number on ART by gender, age, and year; CD4 count 
at ART enrollment by gender, and total population by year. The sources of data used to fit the 
model are listed in Table S1. 
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Table S1. Outputs and sources of data used in calibration 
Output Data Source 
CD4 at ART initiation By gender and category [<100, 
100-200, 200-350] for 2009-2010 
Cornell et al., AIDS 24(14): 2010 
Cornell et al., PLoS Med 9(9): 2012. 
Number on ART By gender and age group 15-49 
and 50+ for 2004-2012 
UNAIDS Spectrum 
Population Estimate of 15-49 population for 
1981-2012 
ASSA 2008 
Prevalence by year, gender, and 
age 
By gender and age groups 15-49 
and 50+ for years 1994-2012 
UNAIDS Spectrum 
Cross-sectional prevalence by 
gender and 5-year age group 
Prevalence by age group and 
gender in years 2002, 2005, and 
2008 
Human Sciences Research Council Surveys 
of South Africa: 2002, 2005, and 2008 
Long-term testing Ever tested by gender in 2002, 
2005, and 2008 
Human Sciences Research Council Surveys 
of South Africa: 2002, 2005, and 2008 
Recent testing 
 
Tested past year by gender in 
2006 and 2009 
 
2009 National HIV Communication Survey of 
South Africa 
Cross-sectional testing Ever tested by age and gender in 
2009 
2009 National HIV Communication Survey of 
South Africa  
 
 
For a given model run, the likelihoods that the model output could be consistent with each 
source of data (Table S1) were multiplied across the data sources to give a single score for the 
model run’s fit to the epidemic. These fitness scores were then averaged across fifty stochastic 
run of the model using the same parameter settings. Because of the large number of data points 
included in the multiplication, typical values for a model that fit well by visual inspection were 
10130 and higher. 
 
To compare CD4 counts at ART enrollment to available data, we accumulated CD4 counts in 
the model over all ART initiations falling within the study interval of CD4 count data(9, 10). For 
each reported CD4 count category, we calculated the model’s proportion of individuals initiating 
ART within this category. The likelihood score was evaluated as the value of the model’s 
outcome in a Gaussian probability distribution characterised by the mean and standard 
deviation of the study data. 
 
For the number receiving ART by year and gender, we similarly calculated the probability of the 
model value in a Gaussian probability distribution, but this time we used the logit-transform of 
both data and model values to ensure non-negative values of the distribution. Number on ART 
was assumed to have 0.5% error in logit space, except prior to 2002, when a 10-fold increase to 
5% variance to was assumed. This is because our data source did not account for the possibility 
of small numbers of individuals receiving ART through the private sector. Testing rates by year 
and by age were similarly evaluated as a Gaussian distribution of logit-transformed data. 
 
We calibrated prevalence by gender and year based on UNAIDS estimates, and prevalence by 
gender and age for three years based on household survey data. Because this provided 
redundant total prevalence information, survey data was used to calibrate the normalized age 
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distribution of prevalence, while UNAIDS estimates were used for the total prevalence across all 
age groups. 
Calibration was performed with iterative rounds of Incremental Mixture Importance Sampling, a 
Bayesian technique that returns samples from the posterior distribution given a likelihood 
function and a prior distribution for the relevant model parameters. After calibration of the pre-
intervention baseline, we used the parameter configuration yielding the maximum a posteriori 
probability to simulate the scenarios.  
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Appendix B: 
Mathematical details of the derivation of the cost and demand 
functions used in estimating the cost, cost effectiveness and cost 
benefit of expansion options for adult ART in South Africa 
In this paper, we model the number of new cases of HIV and disability-adjusted life years 
(DALYs) averted and the cost to the South African government of scaling up the public 
production of antiretroviral treatment services over the period 2014 to 2033 according to a 
number of alternative scenarios. The scenarios differ, first, by the treatment guidelines they 
follow, and second by the economic assumptions regarding two distinct categories of cost: 
production cost and outreach cost. In this appendix we give details of the calculation of both of 
these cost categories, as well as the calculations used in computing DALYs averted, 
incremental cost effectiveness, the cost of orphanhood avoided and the value of productivity 
regained, and, finally, incremental cost benefit. 
Modeling the cost of ART service delivery 
As explained in the text, we distinguish six components of total cost. We conservatively assume 
that only one of these six components, that composed of facility maintenance, personnel and 
other overhead expenditures, is scale dependent, i.e. that its average is sensitive to the number 
of patient-years of ART a facility produces. We assume that the unit costs of the remaining 
components, ARVs, laboratory supplies, HIV testing, and inpatient care, are all insensitive to the 
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number of patient-years of ART produced at each outpatient facility8. In the baseline scenario, 
the scale dependent component is less than a third of total cost. 
Modeling economies of scale 
We model the scale-dependent cost of producing ART services using a version of the simplified 
cost function presented in supplementary materials S2 of [11].  
    𝑡𝑐𝑘𝑡 =  𝐴 𝑛𝑘𝑡𝜎   (1) 
where the total scale-dependent cost at facility k in year t is a function of a constant A9, the 
number of patient-years of treatment the facility delivers in that year, nkt, and the assumed 
elasticity of this cost component with respect to scale, σ. (We abstract from other likely 
determinants of scale-dependent cost at a specific facility such as local prices of maintenance 
supplies and patient characteristics other than their health states). Values of σ less than one 
characterise a cost structure which generates economies of scale. Dividing equation (1) by the 
number of patients served during the year in that facility, nkt, yields the expression for the unit or 
average cost per patient: 
    𝑢𝑐𝑘𝑡 = 𝑎𝑡𝑐𝑘𝑡 =
𝐴 𝑛𝑘𝑡𝜎 𝑛𝑘𝑡⁄ = 𝐴 𝑛𝑘𝑡
𝜎−1  (2) 
 
As described in the text, the model allows the growth in clinic size to follow one of three different 
expansion paths, one informed by the arithmetic mean number of patients per facility which gets 
added to each clinic, one allocating the same proportional growth to all clinics, and lastly a 
pattern following a quadratic equation. The quadratic distribution pattern is intermediate 
between the arithmetic and proportional patterns. For this pattern, we impose the constraint that 
neither the largest nor the smallest facility absorbs more patients, with the incremental 2.9 
million patients being distributed across the middle of the range of facility ranks according to the 
quadratic relationship in equation (3): 
  ∆𝑛𝑘𝑡 = 𝑛𝑘𝑡 −  𝑛𝑘0 = 𝑎𝑡 + 𝑏𝑡 𝑘 + 𝑐𝑡 𝑘2 ∀ 𝑘 = 1, … , 𝐾𝑡  (3) 
where 𝑛𝑘0 is the number of patients served by facility k in the baseline year, 𝑛𝑘𝑡 is the number of 
patients to be served in a future year, ∆𝑛𝑘𝑡 is the increase in the number of patients served 
between the two years and k is an index of the size-rank of the facility ordered from the largest 
for 𝑘 = 1 to the smallest for 𝑘 = 𝐾𝑡. The time subscripts on 𝐾𝑡 and on the parameters capture 
the possibility that the number of facilities might increase over time to accommodate the growing 
number of patients and, in particular, to facilitate access for patients living in rural areas. To find 
                                                          
8 Although the cost of inpatient care is also subject to economies of scale, this is beyond the scope of our paper, as it 
would require information on the scale of each inpatient facility in South Africa, especially since HIV-positive patients 
make up only a subset of all patients assessing inpatient care. 
9 While the parameter A is often treated as a constant and referred to as the “unit cost”, in general it 
varies with the mix of patient health states at facility k in year t.  A health state is defined by type of care (no 
ART, treatment initiation, first line, first-line treatment failure, second line), CD4 cell count stratum (for inpatient cost 
only) and, for children, additionally by age group. 
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the values of parameters 𝑎𝑡, 𝑏𝑡 and 𝑐𝑡 in year t, we solve the following system of three 
equations for those parameters: 
   
∆𝑁𝑡 = ∑ ∆𝑛𝑘𝑡𝐾𝑡𝑘=1 = ∑ [𝑎𝑡 + 𝑏𝑡 𝑘 + 𝑐𝑡 𝑘2]
𝐾𝑡
𝑘=1
𝑎𝑡 + 𝑏𝑡 1 + 𝑐𝑡 1 = 0
𝑎𝑡 + 𝑏𝑡 𝐾𝑡 + 𝑐𝑡 𝐾𝑡2 =  0
  (4) 
The first of these equations requires that ∆𝑁𝑡, the total number of patients added to all facilities 
in the country by year t, be the sum of the patients added to each facility by that year. The 
second and third equations impose the constraints that zero patients be added to the largest 
and smallest facility in that year. Solving the three equations for the three unknown parameters 
yields: 
     
𝑎𝑡 =  
6 ∆𝑁𝑡
(1− 𝐾𝑡)(𝐾𝑡−2)
 < 0
𝑏𝑡 =  
6 ∆𝑁𝑡 (𝐾𝑡+1)
𝐾𝑡(𝐾𝑡−1)(𝐾𝑡−2)
> 0
𝑐𝑡 =  
6 ∆𝑁𝑡
𝐾𝑡(1−𝐾𝑡)(𝐾𝑡−2)
< 0
  (5) 
Since ∆𝑁𝑡 is provided by EMOD-HIV, by modeling an expansion path for the total number of 
facilities, 𝐾𝑡, we can find the values of parameters 𝑎𝑡, 𝑏𝑡 and 𝑐𝑡 in any year t, and then use 
equation (6), derived from equation (3), to distribute the patients across the 𝐾𝑡 facilities in that 
year. The comparable equations for the average and the proportional scale-up programmes are 
equations (7) and (8). 
 𝑛𝑘𝑡  =  𝑛𝑘0 +  𝑎𝑡 + 𝑏𝑡 𝑘 + 𝑐𝑡 𝑘2 ∀ 𝑘 = 1, … , 𝐾𝑡  (6) 
  𝑛𝑘𝑡 =  𝑛𝑘0 + ∆𝑁𝑡 𝐾𝑡⁄  ∀ 𝑘 = 1, … , 𝐾𝑡   (7) 
  𝑛𝑘𝑡 =  𝑛𝑘0  × 𝑁𝑡 𝑁0⁄  ∀ 𝑘 = 1, … , 𝐾𝑡   (8) 
 
 
 
 
Modeling the cost of outreach 
For a given facility at a given level of care and in a given year, we set the upper bound of 
enrollment as equal to the maximum enrollment achieved in that facility under any scenario, 
𝑛𝑘𝑚𝑎𝑥, inflated by the assumed maximum coverage attained at that maximum enrollment, 𝜔. 
Thus, in a given year at a given facility, the degree of enrollment scale up can be defined by the 
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ratio of actual enrollment to this theoretical maximum, 𝑛𝑘𝑡 𝑛𝑘𝑚𝑎𝑥⁄
. Define this proportion, q, for 
both the status quo scenario and the actual scenario as follows: 
     
?̃?𝑘𝑡 =  ?̃?𝑘𝑡 𝑛𝑘𝑚𝑎𝑥
𝜔
⁄
𝑞𝑘𝑡 =  𝑛𝑘𝑡 𝑛𝑘𝑚𝑎𝑥
𝜔
⁄
   (9) 
where 0 <  ?̃?𝑘𝑡 <  𝑞𝑘𝑡 < 1 and 0 < 𝜔 < 1.10 With these definitions, we can write the demand 
function for ART services  
     𝑞𝑘𝑡 =  
1
1−𝑒−𝑑𝑡+𝑒 (−𝑣𝑘𝑡)    (10) 
where 𝑑𝑡 and e are positive parameters and 𝑣𝑘𝑡 >  0 is the per patient outreach expense for 
each patient more than would be recruited in the status quo scenario. For example, the 
outreach expense could be a travel voucher, or could consist of the costs of making home visits 
to the patient. Equation (10) can also be written: 
     𝑙𝑛 𝑞𝑘𝑡(1− 𝑞𝑘𝑡) =  𝑑𝑡 + 𝑒 𝑣𝑘𝑡 .   (11) 
In order to calibrate each facility’s demand curve to predict the status quo demand at a zero 
price, we define the intercept 𝑑𝑡 in terms of the status quo ratio of patients to the maximum 
number: 
     𝑑𝑡 =  𝑙𝑛
?̃?𝑘𝑡
(1− ?̃?𝑘𝑡)
 .    (12) 
If we were predicting the utilisation level for a given level of outreach expenditure, we would use 
equation (11) directly. However, since the number of patients is generated by the epidemiologic 
models (and our selected distribution algorithm), we instead solve equation (11) to obtain the 
inverse demand function which provides the outreach cost per patient required to attract and 
retain at the specified adherence any given number of patients. 
    𝑣𝑘𝑡 =  
[𝑙𝑛 𝑞𝑘𝑡(1− 𝑞𝑘𝑡)
 − 𝑙𝑛 ?̃?𝑘𝑡(1− ?̃?𝑘𝑡)
 ]
𝑒     (13) 
The positive parameter e can be related to the conventional idea of an elasticity of demand. A 
larger value of e, like a larger elasticity of demand, endows this inverse demand function with 
greater sensitivity to the voucher or outreach expenditure, so that a given level of enrollment 
and adherence can be obtained at less cost per patient. Conversely a smaller value of e 
corresponds to a low elasticity and implies that a given level of patient utilization requires a 
                                                          
10 [1] uses a similar logistic specification of demand. 
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larger outreach cost. With reference to Figure 4, a more elastic demand curve would be flatter 
than the one shown and a less elastic one would be steeper. 
In the modeled scenarios, the default value of the “saturation” parameter, 𝜔, varies between 0.7 
for the primary health care facilities, most of which are in relatively dispersed in rural areas, to 
0.9 for the level national and provincial reference hospitals which are located in urban areas and 
assumed to have saturated their local markets. In our baseline runs we set the demand 
elasticity parameter, e, equal to 1.0 for urban facilities and 0.5 for rural facilities. These values 
imply that, other things equal, a larger percentage increase in the travel voucher will be required 
to entice new patients in the more sparsely populated rural area than in the densely populated 
urban area. 
Taken together the model of service delivery cost which incorporates economies of scale and 
the model of outreach cost incorporating various response elasticities allow the overall model to 
characterise the human behavioral responses, on the supply side, of facility and programme 
managers economizing scarce health care inputs and, on the demand side, of patients 
balancing their desire for good health against their other individual and social needs and 
desires. Accurate models of the future cost and success of treatment scale-up depend, inter 
alia, on reliable empirical estimates of the key parameters in these models. On the supply side, 
parameters in need of estimation include the elasticity of each cost component to scale and the 
dependency of these cost components on other features of the economic and institutional 
environment, such as the local prices of inputs and the structure of personnel rewards and 
sanctions. On the demand side, these needed parameters include the elasticity of enrollment 
and adherence with respect to outreach expenses, as modeled here. 
Calculating incremental cost per infection or DALY averted 
In this analysis, the cost-effectiveness of scenario x over a comparator scenario b (e.g. G0.SQ) 
is defined as the incremental cost of scenario x per incremental infection or per DALY averted.  
1. The number of HIV infections for each scenario is generated by EMOD-HIV; the incremental 
number of infections is simply the difference between the number of infections in scenario x 
over scenario b. The incremental number of DALYs averted is calculated as the sum of all life 
years lived by each HIV-positive individual in a particular health state across the 20 years of 
projection multiplied by the utility weight (set equal to 1 - the disability weight) for this health 
state, according to equation (14):  
𝐼𝑛𝑐𝐷𝐴𝐿𝑌𝑠𝑥𝑏 =  ∑ ∑  𝑛𝑖𝑡𝑥 (1 − 𝑑𝑖) (1+𝑟)−(𝑡)𝑖∈𝐼𝑡∈𝑇  −  ∑ ∑ 𝑛𝑖𝑡𝑏(1 − 𝑑𝑖) (1+𝑟)−(𝑡)𝑖∈𝐼𝑡∈𝑇   (14) 
where IncDALYsxb is the incremental cost of scenario x relative to scenario b, T the total number 
of years t in the model, I the total number of health states i in the model, 𝑛𝑖𝑡𝑥 the number of HIV-
infected people in health state i and year t under scenario x, di the disability weight for health 
state i, and r the discount rate (3% at baseline, varied to 0%, 5% and 10% in sensitivity 
analysis). The second term in equation (14) computes the number of DALYs for scenario b, and 
the incremental number of DALYs averted is the difference between the two terms. 
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2. The numerator for the incremental cost-effectiveness ratios, incremental cost, is defined by 
equation (2): 
𝐼𝐶(ℎ𝑖𝑣)𝑥𝑏 =  ∑ ∑ ∑ 𝑛𝑖𝑘𝑡𝑥𝑢𝑐𝑖𝑘𝑡𝑥𝑘∈𝐾𝑡 (1+𝑟)−(𝑡)𝑖∈𝐼𝑡∈𝑇  −  ∑ ∑ ∑ 𝑛𝑖𝑘𝑡𝑏𝑢𝑐𝑖𝑘𝑡𝑏𝑘∈𝐾𝑡 (1+𝑟)−(𝑡)𝑖∈𝐼𝑡∈𝑇   
 (15) 
where IC(hiv)xb is the incremental cost of HIV-related care in scenario x relative to scenario b, Kt 
the total number of facilities delivering ART in year t,  𝑛𝑖𝑘𝑡𝑥 the number of HIV-infected people in 
health state i, facility k, and year t under scenario x, and 𝑢𝑐𝑖𝑘𝑡𝑥 the per-person year cost of HIV-
related care for this health state in this facility and year. Again, the second term in equation (15) 
computes the same cost for scenario b, and the incremental cost is the difference between the 
two terms. As discussed in the text and in our previous publication [11], the per-person year 
cost for a given year and health state and scenario, 𝑢𝑐𝑖𝑘𝑡𝑥, is not a fixed constant, but rather a 
function of the year t supply- and demand-side characteristics of the k’th facility in which it is 
produced.  
Calculating the cost of orphanhood and the value of productivity 
In order to quantify the benefits of ART provision under any scenario of eligibility and coverage, 
we calculated the number of maternal orphans under each scenario and allocated the cost of 
orphan care to each of them, then calculated the increment for each scenario over baseline 
scenario b using equation (16): 
𝐼𝐶(𝑜𝑟𝑝ℎ𝑎𝑛ℎ𝑜𝑜𝑑)𝑥𝑏 =  ∑ ∑ 𝑛𝑎𝑡𝑥 𝑝(𝑜𝑣𝑐) 𝑢𝑐𝑎 (1+𝑟)−(𝑡)𝑎∈𝐴𝑡∈𝑇 − ∑ ∑ 𝑛𝑎𝑡𝑏 𝑝(𝑜𝑣𝑐) 𝑢𝑐𝑎 (1+𝑟)−(𝑡)𝑎∈𝐴𝑡∈𝑇  
 (16) 
where IC(orphanhood)xb is the incremental cost of HIV-related care in scenario x relative to 
scenario b, A the total number of age groups a,  𝑛𝑎𝑡𝑥 the number of maternal orphans in age 
group a and year t under scenario x, 𝑝(𝑜𝑣𝑐) is the percentage of orphans needing care and 
support (modelled on the percentage of the population living below the poverty line (upper 
bound) [21]) and 𝑢𝑐𝑎 the per-person year cost of orphan care for this age group. As above, the 
second term in equation (16) computes the same cost for scenario b, and the incremental cost 
is the difference between the two terms. 
Treatment benefits in terms of regained productivity were calculated based on the number of 
adults of working age multiplied by the Gross National Income per working-age person and 
health-state specific productivity weights: 
𝐼𝑃𝑥𝑏 =  ∑ ∑ 𝑛𝑖𝑡𝑥 𝑝(𝑤𝑎)𝑥 𝑝𝑤𝑖 𝐺𝑁𝐼𝑤𝑎 (1+𝑟)−(𝑡)𝑖∈𝐼𝑡∈𝑇  − ∑ ∑ 𝑛𝑖𝑡𝑥 𝑝(𝑤𝑎)𝑏 𝑝𝑤𝑖 𝐺𝑁𝐼𝑤𝑎 (1+𝑟)−(𝑡)𝑖∈𝐼𝑡∈𝑇  
 (17) 
where IPxb is the incremental productivity in scenario x relative to scenario b, 𝑛𝑖𝑡𝑥 the number of 
adults with HIV in health state i and year t under scenario x, 𝑝(𝑤𝑎)𝑥 is the percentage of adults 
being of working age, 𝑝𝑤𝑖 the productivity weight for health state i, and 𝐺𝑁𝐼𝑤𝑎 the Gross 
National Income per working-age adult. As above, the second term in equation (17) computes 
the same cost for scenario b, and the incremental cost is the difference between the two terms. 
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Calculating the incremental cost benefit of ART 
Based on equations (15), (16) and (17), we calculate the incremental cost benefit of ART of 
each scenario over the baseline scenario (𝐼𝐶𝐵𝑥𝑏) as the incremental HIV-related cost minus the 
incremental cost of orphanhood averted and divide this by the incremental value of gained 
productivity 𝐼𝑃𝑥𝑏, following equation (18): 
    𝐼𝐶𝐵𝑥𝑏 =  (𝐼𝐶(ℎ𝑖𝑣)𝑥𝑏 − 𝐼𝐶(𝑜𝑟𝑝ℎ𝑎𝑛ℎ𝑜𝑜𝑑)𝑥𝑏)/𝐼𝑃𝑥𝑏  (18) 
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Appendix C:  
Annual undiscounted cost by year and for the 2014-2016 mid-term 
expenditure framework for all scenarios [2013 USD] 
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Undiscounted annual cost 
by 30 June of year 2014 2015 2016 
2014-
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 
CG.SQ                      
Total cost (all patients) 1,856 1,963 2,045 5,865 2,117 2,181 2,235 2,286 2,330 2,374 2,417 2,455 2,490 2,528 2,559 2,591 2,618 2,645 2,671 2,694 2,713 
Total cost (patients on ART) 1,272 1,387 1,477 4,136 1,557 1,622 1,678 1,729 1,774 1,819 1,862 1,898 1,932 1,970 2,001 2,033 2,060 2,086 2,113 2,136 2,156 
Total cost (patients off ART) 395 384 373 1,153 363 359 355 354 351 349 347 347 346 345 343 341 340 339 336 335 332 
Total cost (testing) 189 192 195 576 197 200 202 203 205 206 208 210 211 213 215 216 218 219 222 223 225 
CG.UE                        
Total cost (all patients) 2,283 2,759 2,870 7,912 2,984 3,086 3,171 3,252 3,325 3,386 3,443 3,497 3,544 3,590 3,628 3,665 3,700 3,734 3,741 3,763 3,780 
Total cost (patients on ART) 1,570 1,966 2,134 5,671 2,274 2,390 2,488 2,576 2,654 2,718 2,777 2,831 2,877 2,922 2,958 2,991 3,024 3,052 3,055 3,068 3,080 
Total cost (patients off ART) 338 261 221 821 196 181 165 151 140 130 123 115 107 101 96 90 85 82 78 76 73 
Total cost (testing) 374 531 515 1,420 513 516 518 525 531 538 544 551 559 567 574 583 591 601 608 618 628 
UTT.SQ                        
Total cost (all patients) 1,912 2,079 2,198 6,189 2,290 2,356 2,408 2,457 2,496 2,522 2,544 2,572 2,594 2,614 2,629 2,645 2,658 2,672 2,686 2,696 2,703 
Total cost (patients on ART) 1,339 1,523 1,661 4,523 1,767 1,844 1,905 1,958 2,001 2,032 2,059 2,084 2,109 2,128 2,144 2,159 2,171 2,185 2,199 2,207 2,215 
Total cost (patients off ART) 384 364 342 1,090 326 314 302 297 290 285 278 278 274 273 270 269 267 265 262 262 258 
Total cost (testing) 189 192 195 575 197 198 200 202 204 206 207 209 211 213 215 217 219 222 225 227 230 
UTT.UE                        
Total cost (all patients) 2,479 3,023 3,087 8,589 3,141 3,183 3,217 3,247 3,277 3,302 3,322 3,342 3,361 3,379 3,391 3,404 3,414 3,422 3,429 3,433 3,438 
Total cost (patients on ART) 1,812 2,308 2,431 6,551 2,505 2,557 2,593 2,624 2,652 2,676 2,695 2,712 2,727 2,739 2,747 2,754 2,759 2,760 2,760 2,756 2,754 
Total cost (patients off ART) 292 184 141 618 122 108 101 93 86 79 73 69 63 60 56 53 50 47 44 42 40 
Total cost (testing) 375 531 515 1,420 514 518 523 531 539 547 554 562 570 579 587 596 606 616 625 635 644 
500.SQ                        
Total cost (all patients) 1,900 2,052 2,169 6,121 2,256 2,319 2,374 2,422 2,459 2,492 2,521 2,548 2,573 2,596 2,622 2,640 2,659 2,676 2,689 2,701 2,720 
Total cost (patients on ART) 1,323 1,494 1,625 4,443 1,725 1,802 1,864 1,914 1,957 1,992 2,023 2,050 2,075 2,098 2,122 2,142 2,159 2,174 2,189 2,201 2,217 
Total cost (patients off ART) 387 366 349 1,102 334 319 309 305 298 294 291 289 287 286 285 282 282 280 277 275 275 
Total cost (testing) 189 192 195 575 197 199 200 202 204 206 208 209 211 213 215 217 218 223 223 226 228 
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500.UE                      
Total cost (all patients) 2,441 2,999 3,080 8,520 3,143 3,189 3,227 3,263 3,294 3,323 3,345 3,370 3,390 3,410 3,426 3,441 3,453 3,463 3,471 3,477 3,484 
Total cost (patients on ART) 1,764 2,271 2,416 6,450 2,502 2,558 2,600 2,636 2,667 2,694 2,715 2,736 2,754 2,769 2,780 2,790 2,795 2,799 2,800 2,798 2,798 
Total cost (patients off ART) 303 197 149 648 128 114 105 97 90 84 78 73 68 64 60 56 53 50 48 45 43 
Total cost (testing) 375 531 515 1,421 513 517 522 530 538 545 552 561 569 577 586 596 604 614 623 633 644 
DC.SQ                        
Total cost (all patients) 1,848 1,956 2,038 5,842 2,108 2,169 2,226 2,278 2,324 2,371 2,413 2,452 2,487 2,520 2,554 2,588 2,614 2,641 2,667 2,690 2,708 
Total cost (patients on ART) 1,265 1,383 1,472 4,120 1,547 1,612 1,670 1,721 1,769 1,815 1,857 1,895 1,932 1,964 1,997 2,030 2,058 2,083 2,110 2,132 2,150 
Total cost (patients off ART) 394 380 371 1,145 363 357 354 352 349 347 347 346 343 342 341 341 337 337 334 334 332 
Total cost (testing) 189 192 195 577 198 200 202 204 206 209 209 211 213 214 216 218 218 221 223 224 226 
DC.PE                        
Total cost (all patients) 2,083 2,414 2,544 7,040 2,644 2,731 2,806 2,873 2,937 2,987 3,040 3,091 3,137 3,182 3,226 3,263 3,302 3,340 3,372 3,406 3,435 
Total cost (patients on ART) 1,435 1,754 1,931 5,119 2,057 2,161 2,246 2,318 2,385 2,441 2,495 2,547 2,595 2,641 2,685 2,722 2,760 2,795 2,827 2,860 2,888 
Total cost (patients off ART) 371 318 277 966 251 234 221 209 204 194 188 182 175 172 166 161 157 152 148 143 138 
Total cost (testing) 277 342 336 955 336 337 340 345 348 352 357 361 366 369 375 380 386 392 397 403 409 
DC.UE                        
Total cost (all patients) 2,286 2,808 2,935 8,030 3,057 3,151 3,225 3,294 3,352 3,401 3,444 3,482 3,517 3,545 3,572 3,597 3,620 3,640 3,654 3,669 3,678 
Total cost (patients on ART) 1,575 2,019 2,212 5,807 2,363 2,475 2,561 2,635 2,697 2,747 2,792 2,828 2,861 2,889 2,912 2,933 2,949 2,962 2,973 2,981 2,983 
Total cost (patients off ART) 336 255 206 798 178 158 142 131 120 113 104 97 91 85 82 76 74 70 67 63 61 
Total cost (testing) 375 534 517 1,426 515 518 521 528 534 541 548 556 565 570 579 588 597 608 615 624 634 
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PW.SQ                      
Total cost (all patients) 2,441 2,999 3,080 8,520 3,143 3,189 3,227 3,263 3,294 3,323 3,345 3,370 3,390 3,410 3,426 3,441 3,453 3,463 3,471 3,477 3,484 
Total cost (patients on ART) 1,764 2,271 2,416 6,450 2,502 2,558 2,600 2,636 2,667 2,694 2,715 2,736 2,754 2,769 2,780 2,790 2,795 2,799 2,800 2,798 2,798 
Total cost (patients off ART) 303 197 149 648 128 114 105 97 90 84 78 73 68 64 60 56 53 50 48 45 43 
Total cost (testing) 375 531 515 1,421 513 517 522 530 538 545 552 561 569 577 586 596 604 614 623 633 644 
PW.PE                        
Total cost (all patients) 1,848 1,956 2,038 5,842 2,108 2,169 2,226 2,278 2,324 2,371 2,413 2,452 2,487 2,520 2,554 2,588 2,614 2,641 2,667 2,690 2,708 
Total cost (patients on ART) 1,265 1,383 1,472 4,120 1,547 1,612 1,670 1,721 1,769 1,815 1,857 1,895 1,932 1,964 1,997 2,030 2,058 2,083 2,110 2,132 2,150 
Total cost (patients off ART) 394 380 371 1,145 363 357 354 352 349 347 347 346 343 342 341 341 337 337 334 334 332 
Total cost (testing) 189 192 195 577 198 200 202 204 206 209 209 211 213 214 216 218 218 221 223 224 226 
PW.UE                        
Total cost (all patients) 2,083 2,414 2,544 7,040 2,644 2,731 2,806 2,873 2,937 2,987 3,040 3,091 3,137 3,182 3,226 3,263 3,302 3,340 3,372 3,406 3,435 
Total cost (patients on ART) 1,435 1,754 1,931 5,119 2,057 2,161 2,246 2,318 2,385 2,441 2,495 2,547 2,595 2,641 2,685 2,722 2,760 2,795 2,827 2,860 2,888 
Total cost (patients off ART) 371 318 277 966 251 234 221 209 204 194 188 182 175 172 166 161 157 152 148 143 138 
Total cost (testing) 277 342 336 955 336 337 340 345 348 352 357 361 366 369 375 380 386 392 397 403 409 
 
